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ABSTRACT 
 
Alexia Genese Smith 
Obesity Affects the Immune Response to Influenza Virus Infection - A Mechanism for 
Immune Modulation 
(Under the direction of Melinda A. Beck) 
 
 The incidence of obesity worldwide has reached epidemic proportions. This has had a 
significant economic and social impact due to the increase in co-morbidities associated with 
obesity (1). Obesity leads to changes in immune parameters under basal conditions (2), 
suggesting that obesity may result in impaired immune responses during an infection. 
Influenza virus infection is a leading cause of morbidity and mortality worldwide, and proper 
immune regulation is necessary for clearance of virus with minimal damage to the host. 
Given that obesity leads to impairment in immune function, we hypothesized that obesity 
would result in an impaired immune response following infection with influenza virus.  
 
 Using a mouse model of diet-induced obesity, we found that influenza infected mice 
had minimal and delayed activation of the innate immune response, as well as a mortality 
rate that was eight times greater than normal weight mice. The lack of response was partially 
due to a reduction in mononuclear cell infiltration into the lungs during the early stages of 
infection. Obese mice also had impaired dendritic cell function, which is a critical link 
between the innate and cell-mediated immune responses, suggesting that cell-mediated 
responses during influenza infection were also affected by obesity. Indeed, obese mice had
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 lower induction of cytokines that promote anti-viral T cell responses, impaired proliferation 
and cytokine production by T cells, and delayed infiltration of T cells to the infected lung. 
 
 What was the cause of the immune dysfunction? Once possibility was the high 
circulating leptin levels found in obese mice. Leptin is a hormone that plays a role in both 
innate and cell-mediated immunity through phosphorylation of Signal transducer and 
activator of transcription 3 (STAT3) subsequent to binding to its receptor. Despite high 
circulating leptin, we found that obese mice had reduced STAT3 phosphorylation in immune 
cells during infection, indicating leptin signaling was impaired and may have mediated some 
of the immune changes that occurred in obese mice. When we analyzed the impact of direct 
leptin on immune cell function, we found that direct leptin signaling was not required for 
normal function. This was shown by correction of immune cell function when a functional 
neuro-specific leptin receptor was expressed in leptin receptor-deficient, db/db mice. 
Therefore, the impairment in immune responses that occur in obese mice is, in part, likely 
due to a lack of centrally mediated effects of leptin.  
 
 Overall, this work implicates obesity as a risk factor for impaired immune responses 
during influenza virus infection and, furthermore, suggests that responses to other infections 
may be affected by obesity. Thus, the rapidly growing obese population in this country and 
other may at substantial risk for increased morbidity and mortality during the next influenza 
pandemic. 
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BACKGROUND AND SIGNIFICANCE 
 
A.  Specific Aims 
 
 The incidence of obesity worldwide has reached epidemic proportions. This has had a 
significant economic and social impact due to the increase in co-morbidities associated with 
obesity (1, 20). Obesity leads to changes in immune parameters under basal conditions (2), 
and therefore suggests that obesity may result in impaired immune responses during an 
infection.  
 Influenza virus infection is a leading cause of morbidity and mortality, and proper 
immune regulation is necessary for clearance of virus with minimal damage to the host. 
Given the impairment in immune function observed in obesity, we hypothesized that 
obesity would result in dysregulation of the immune responses during influenza virus 
infection. The present studies outline a series of experiments that addressed the role of 
obesity on modulating innate and cell-mediated immune responses during influenza virus 
infection. 
 
Specific Aims 
 
1.   Determine if innate immune responses are impaired in influenza infected obese mice. 
2.  Determine if the cell mediated immune responses are impaired in obese mice infected   
with influenza virus. 
3.   Determine the role of leptin in immune changes in obese mice during influenza infection.
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B.  Obesity: A Public Health Perspective 
 
 Obesity rates, worldwide, are at an all time high and continue to escalate. In the 
United States greater than 60% of the population is overweight or obese. Because obesity is a 
major risk factor for metabolic syndrome, Type 2 Diabetes, and cardiovascular disease, 
prevalence of these diseases has increased as well. In addition to its adverse effects on 
metabolic diseases, obesity also results in impaired immune function (23-25), although little 
is known about the impact of obesity on infectious disease. Obesity is a significant 
contributor to health care costs due to the increase in co-morbidities associated with it. 
Raebel et al reported that the cost of healthcare for an obese individual was 250 dollars more 
per year than non-obese individuals (28). More importantly, the pervasiveness of obesity has 
extended to the young and it is so dramatic that a potential decline in lifespan has been 
proposed for the next generation (29).   
 
C. Animal Models of Obesity 
 
 Obesity in humans is primarily the result of an imbalance in caloric intake and caloric 
expenditure (30, 31). In mice, obesity can develop in the same way through feeding of a high 
fat diet. C57BL/6 mice are one of the most commonly used strains for diet induced obesity. 
When fed a high fat diet these mice develop significant increases in adipose tissue mass, 
circulating glucose, insulin, and leptin (32, 33). The effects of the high fat diet in C57BL/6 
mice are analogous to humans, making it an excellent model for studies related to obesity. 
 
 Many other mouse models of obesity exist that do not rely on dietary manipulation. 
These include single-gene loss-of-function, both natural and artificially derived, transgenic 
models, and polygenic models (34). Two of the most commonly used genetic mouse models 
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of obesity are the ob/ob and db/db models, both of which have single-gene loss-of-function 
leading to a premature stop codon in the leptin gene and abnormal splicing of the long form 
of leptin receptor, respectively. The lack of leptin signaling in these mice leads to extreme 
hyperphagia, hyperglycemia, and hyperleptinemia, as well as hypercorticosteronemia and 
infertility (35, 36), effects which are not normally seen in obese humans (37). 
 
D. Obesity as a Modulator of Immune Function 
 
Obesity is implicated in immunosuppression in both humans and mice (23, 25, 38). In 
humans, obesity has been shown to be a risk factor for infections and poor wound healing 
after a variety of surgical procedures (23, 25), as well as for increasing the risk of infection 
and sepsis in burn patients (24). Additionally, obesity results in changes in the circulating T 
cell population (2) and diminished bacterial killing capacity of polymorphonuclear cells (39).   
 
Numerous studies done in genetically obese mice indicate a global impairment in 
immune function in these mice (40-45). For example, they have marked thymic atrophy, and 
fewer splenic mononuclear cells and T cells (41, 43). Additionally, genetically obese mice 
have decreased resistance to bacterial and viral infections (38, 43), as well as reduced cell 
mediated cytotoxicity (45, 46). While the use of these mice allows for research in a model 
with extreme adiposity, the complete lack of leptin signaling leads to phenotypic changes that 
can affect immune responses and are considerably more pronounced that what occurs in diet-
induced obesity in humans and mice (17, 47).  
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Studies of immune function in diet-induced obese (DIO) mice have focused primarily 
on mononuclear cell function ex vivo (48-51) with little work done in regard to immune 
responses to infectious disease (52).  However, the current research does indicate that diet 
induced obesity also impairs immune function. For example, diet-induced obese mice have 
impaired antigen presentation and stimulation of T cell proliferation (53), while rats fed a 
cafeteria diet to induce obesity, display helper T cell lymphopenia and decreased natural 
killer (NK) cell function (48, 49). Additionally, DIO mice have decreased hepatic NKT cells 
and alterations in mitogen stimulated splenocyte proliferation and cytokine production (50, 
51).  So, there is clearly a dysregulation of immune function in DIO mice.  
 
It is currently unknown why obesity leads to changes in immune function, but many 
pathways that are altered during obesity have important roles in immune responses. These 
include: nuclear factor kappa B (NF-κB), Phosphoinositide-3 kinase (PI3K), glucocorticoids, 
catecholamines, and adipokines (See Table 1.1). Adipokine modulation of immune function, 
particularly leptin, is the best characterized link between obesity and immune function where 
it appears to be essential for appropriate function (8).  
 
 
 
 
 
 
 
 5 
Table 1.1. Factors that may link obesity and immune function 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Factor Metabolic Effect Immune Effect During obesity References 
Adiponectin + AMPK 
+ GLUT4 
- SREBP1 
Anti-
inflammatory 
  - NF-κB 
  + PPARα 
  - Scavenger R 
on macrophage 
Reduced (3-5)  
Leptin + Lypolysis 
- Food intake 
+ PI3K 
 
 Inflammatory 
   +NFκB 
   +JAK/STAT 
+ Th1  
Increased (but 
downregulation of 
signal) 
(6-8) 
Glucose (High) + Insulin  
+ROS 
+PKC 
Inflammatory 
  +NFκB 
  +JNK, p38 
 
Increased (9, 10) 
FFA - Insulin-stimulated 
  glucose uptake 
+ PKCθ 
+ IKK 
+ JNK 
Increased/no 
change  
(no change in 
DIO mice) 
(11-13) 
Insulin + Glucose uptake 
- Food intake 
- Lypolysis 
- Inflammation Increased (but 
downregulation of 
signal) 
(14) 
Macrophage in 
WAT 
- PI3K + Local NFκB 
+inflammation 
Increased (15) 
(16) 
Catecholamine 
     NE 
     EPI 
+Lypolysis 
- Adipocyte 
    proliferation 
+ Thermogenesis 
+/- Th2/Th1 
- NK cell activity 
Increased NE 
Decreased EPI 
(17-19) 
Glucocorticoids + Adipogenesis 
+ Gluconeogenesis 
+ Food intake 
-NK cell activity 
- Inflammation 
Increased / no 
change 
(17, 21) (22) 
Neuropeptides 
    NPY 
    POMC 
- Lipolysis 
+ Food intake 
+ Ag presentation 
- T cell response 
Increased/no 
change NPY 
Decreased POMC 
(26, 27) 
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1.  Adipokine release from adipose tissue  
 Adipose tissue is now recognized as a major endocrine and secretory organ (54), 
secreting molecules that function in a variety of physiological pathways, such as regulation 
of food intake (55), angiogenesis (56), and immune responses (57). The molecules that 
mediate these effects are collectively known as adipokines, which are are secreted by adipose 
tissue and act on cells in an autocrine and paracrine manner. For example the adipokine 
leptin is produced mainly by adipocytes and acts in the hypothalamus to decrease food 
intake, but also signals adipocytes to induce lipolysis (58). Leptin and adiponectin are the 
most abundantly produced adipokines, but resistin and visfatin are also important adipokines 
(3).  Other adipokines include molecules that are classically associated with the immune 
response, such as IL-6, TNF-α, and C-reactive protein (59).   
 
 2. Leptin 
 
 Leptin is the 16 kDa product of the ob gene that is produced primarily by adipocytes 
and is member of the family of long helical cytokines (60). Leptin increases proportionately 
to adipose mass, and therefore circulates at high levels in obesity (61). Through central and 
peripheral actions leptin regulates adiposity, fertility, glucose tolerance, and immune function 
(62-64).  
 
 Leptin acts in several regions of the hypothalamus, but leptin signaling is most readily 
detectable in the arcuate nucleus in two distinct neuronal populations.  One population 
synthesizes neuropeptide Y (NPY) and agouti-related peptide (AgRP) and the other 
synthesizes pro-opiomelanocortin (POMC). NPY and AgRP are orexigenic neuropeptides 
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that suppress Ob-Rb mediated growth and reproduction. Leptin inhibits their expression 
while at the same time activating the anorexigenic neuropeptide POMC and its downstream 
effector α melanocyte-stimulating hormone (αMSH) (65, 66).  
 
 Leptin also mediates it effects via direct action on peripheral cells. In adipose tissue, 
for example, adenovirus induced overexpression of leptin leads to fat depletion in both intact 
and denervated fat pads, whereas no change in mass occurs in fat pads from fa/fa rats which 
lack leptin receptors (67). Similarly, leptin also appears to exert direct action on immune 
cells. For instance, Tian et al. demonstrated that leptin directly enhances NK cell cytolytic 
activity. When ex vivo cytotoxicity assays were performed in the presence of IL-15, an 
activator of NK cells, NK cells from both WT and db/db mice display normal killing 
capacity. However, the addition of leptin augmented the cytotoxic function of WT NK cells, 
whereas in NK cells from db/db mice it had no effect (68).  
 
2.1  Leptin Signaling 
 The leptin receptor protein is a member of the class I cytokine receptor family (69). 
Many splice variants of leptin receptor exist and include Ob-Ra, Ob-Rb, Ob-Rc, Ob-Rd, Ob-
Re, and Ob-Rf (70), which are classified as short, long, and secreted.  All five isoforms share 
a common ligand binding domain, but differ in the length of their intracellular domains. The 
secreted form of Ob-R (E) has been shown to bind circulating leptin, while the function of 
the short forms (A, C, D, and F) are thought to aid in leptin transport across the blood brain 
barrier (71). Only the B isoform has signaling capabilities as its intracellular domain contains 
the various motifs required for the interaction of signaling molecules (70, 72).  
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 Upon binding to its receptor, leptin stimulates three main signaling cascades that 
begin with the phosphorylation of tyrosine residues on the receptor’s intracellular domain by 
a noncovalently bound Janus kinase (JAK) (73). Specifically, JAK2 leads to the activation of 
signal transducers and activators of transcription (STAT) signaling pathway, the PI3K 
pathway, and the mitogen-activated protein kinase (MAPK) pathway.  
 
 Activation of the PI3K pathway occurs through insulin-receptor substrate (IRS)-2 and 
mediates some of leptin’s anorectic effects. This is evidenced by an increase in feeding and a 
decrease metabolic rate in IRS-2 knock out mice despite of high leptin levels (74). Moreover, 
inhibition of PI3K activity in the hypothalamus attenuates leptin-mediated hyperpolarization 
of NPY/AgRP neurons (75). PI3K signaling is also required for leptin mediated sympathetic 
nervous system activation (76).  
 
 The effects of leptin activation on the MAPK signaling pathway are less well defined, 
but it appears that the immunomodulatory effects of leptin are mediated through constituents 
of this pathway. Leptin signaling through the Ras/Raf/MAPK cascade leads to the activation 
of genes involved in cell proliferation and differentiation (65). Additionally, leptin also 
increases p38 phosphorylation in mononuclear cells, suggesting that its ability to promote T 
cell survival (77) is mediated through this pathway (78).  Activation of Ob-Rb also stimulates 
JNK (c-Jun N-terminal kinase), a stress-activated protein kinase that is activated by 
cytokines. Interestingly, activation of p38 and JNK have been shown to enhance IL-1β-
mediated vascular epithelial cell adhesion molecule (VCAM)-1 in human tracheal smooth 
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muscle cells (79), an effect that is important for leukocyte extravasion across the vascular 
endothelium (80). Additionally, leptin has been shown to enhance TNFα production in 
Kupffer cells through this pathway (81). Therefore, leptin augmentation of immune 
responses may be mediated through this pathway.  
 
 The phosphorylated Ob-Rb also recruits signal transducers and activators of 
transcription (STAT) to the receptor complex. STAT3, 5, and 6 mediate the transcriptional 
effects of leptin upon entry into the nucleus (82). STAT3, in particular, has been shown to 
mediate a number of leptin’s effects. This was shown in mice that had a mutation in the 
tyrosine residue required for STAT3 recruitment to Ob-Rb (s/s mice). In comparison to db/db 
mice, s/s mice were; more fertile, normal length, and less hyperglycemic. Additionally, these 
mice had relatively normal hypothalamic NPY levels, but had low POMC expression and 
were extremely obese (83). This indicates that STAT3 mediates leptin’s effects on the 
melanocortin system and adipose accumulation, and points towards another pathway for 
affecting NPY, reproduction, and glucose homeostasis.   Additionally STAT3 mediates 
leptin’s effects of growth and function of cells through activation of genes such as activator 
protein-1, c-fos, and egr-1 (84, 85).  
 
 STAT3 functions in a number of other pathways, including IL-6, IL-10 and IL-27 
signaling (86). The overall effect of these pathways appears to be anti-inflammatory, since 
mice that have a targeted STAT3 deletion in macrophage and granulocytes develop 
enterocolitis and a hypersensitivity to LPS shock (87). Given that leptin generally promotes 
inflammation, it is unclear what role the STAT3 pathway has on leptin modulation of 
immune responses.  
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 Leptin signaling is negatively regulated by feedback inhibitors and autoregulation.   
In accordance with other activators of JAK/STAT signaling, STAT3 induces suppressor of 
cytokine signaling proteins, (SOCS), and specifically SOCS3. SOCS3 is recruited to the 
phosphorylated tyrosines on the receptor and prevents JAK2 phosphorylation (88) leading to 
attenuation of Ob-Rb signaling.  An increase in SOCS3 leads to downregulation of all Ob-Rb 
signaling pathways (88, 89).  Additional regulation occurs at the receptor level where leptin 
signaling causes a downregulation of Ob-Rb expression (90).  
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Figure 1.1 Leptin signaling through Ob-Rb (71) 
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2.2 Leptin Resistance 
With the discovery of leptin, many thought the cure for obesity had been found. 
However, the limited effect exogenous leptin had on obese humans, and the fact that they 
already had high circulating leptin, indicated that signaling by leptin may be diminished (71) 
Evidence for both central and peripheral leptin resistance is mounting. For instance, 
attenuated leptin signaling with a concomitant increase in SOCS3 levels occurred in the 
hypothalamus during leptin administration to ob/ob mice (91). In diet-induced obese rats, 
chronically high leptin resulted in downregulated expression of leptin receptor in liver and 
kidney. In the kidney, the number of leptin binding sites was inversely correlated with the 
concentration of serum leptin (92). In another rat model of diet-induced obesity, a decrease in 
leptin receptor expression was seen under basal conditions and leptin binding to its receptor 
was reduced upon bolus injection of leptin. Furthermore, post receptor signaling was 
completely abolished in the livers of obese rats following leptin injection compared to lean 
controls (93). This has been more recently shown in T cells from obese mice. Diet-induced 
obese mice were injected with leptin and STAT3 DNA binding was examined in T cells. This 
study found that while there was a 5 fold increase in STAT3 binding in lean mice, there was 
no change from baseline in obese mice (77).  In this study, it was hypothesized that an 
upregulation of SOCS3 led to the reduction in STAT3, because there was no difference in 
Ob-Rb on the cell surface.  
 
The mechanism of leptin resistance is predominantly thought to be an increase in 
SOCS3 protein (71) due to continual stimulation of Ob-Rb in obesity. However, other studies 
indicate that decreased central and peripheral Ob-Rb mRNA expression (90, 94) in the 
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setting of chronically high leptin, as well as a reduction in leptin binding sites (92) may be to 
blame. Therefore in an environment where leptin concentration is continually elevated, leptin 
signaling may be impaired. 
 
2.3 Leptin and Immune Function  
Though originally described as a satiety hormone, leptin’s ability to modulate 
immune function was discovered when db/db mice were found to have thymic atrophy (55). 
It is now clear that leptin has direct and indirect effects on both innate and cell-mediated 
immune response. In fact, the drop in leptin is thought to be, in part, responsible for the 
immunosuppression that occurs during starvation, as leptin administration abrogated the 
immune defects in mice following a 48h fast (6).  Immunomodulatory effects of leptin 
include; NK cell development and cytotoxicity (95), upregulation of pro-inflammatory 
cytokines, and T cell proliferation and activation (6, 8, 96, 97). Leptin can induce cytokine 
production by dendritic cells (98) and macrophages, as well as promoting NK cell 
cytotoxicity and type I helper T cell responses (8).   
 
2.3.1 Innate Immune Responses 
 
Leptin’s effects on innate immune responses are generally thought to increase an 
inflammatory response, seeing that leptin increases during an infection and augments the 
secretion of the pro-inflammatory cytokines IL-1β, TNFα and IL-6 (99).  Leptin’s role in 
inflammation is also demonstrated in models of inflammatory diseases. In experimentally 
induced colitis, mice that lack leptin (40) are protected from the intestinal inflammation and 
have less pro-inflammatory cytokine secretion. However, administration of leptin increases 
cytokine production in these mice to that of controls (100).  In addition to its role in 
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inflammation, leptin also promotes the secretion of cytokines from dendritic cells. Analysis 
of dendritic cells stimulated with lipopolysaccharide (101) and leptin, demonstrated 
synergistic effects on cytokine production than cells cultured with LPS alone (98). Similarly, 
leptin increases phagocytosis and cytokine secretion from monocytes and macrophage (97). 
Moreover, leptin promotes NK cell development and cytotoxicity as demonstrated by 
impaired NK cell function in db/db mice, which lack the leptin receptor (102).  
 
2.3.2 Cell-Mediated Immune Responses 
 
 
Analogous to innate responses, cell mediated immune responses are also affected by 
leptin. In CD4 T cells, leptin promotes IFNγ production, thus polarizing a Th1 response (103, 
104). Evidence of this has been shown in children who lack leptin. These children have 
significantly impaired T cell proliferative responses and IFNγ production following mitogen 
stimulation. This is corrected, however, once leptin supplementation is initiated (103). Leptin 
also induces T cell proliferation and survival, IL-2 secretion, and adhesion molecule 
expression (6, 77, 97). Administration of leptin to ob/ob, as well as mice with starvation-
induced leptin deficiency, reverses immunosuppression (6)..   
 
 
 
 
 
 
 
 15 
Figure 1.2. Leptin’s action on cells of the immune system 
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E. Influenza A: A Public Health Perspective 
  Influenza infection affects millions every year. In the United States it is responsible 
for over 36,000 deaths and 200,000 hospitalizations, making it the sixth leading cause of 
death (105). Worldwide it is estimated 5-40% of the population is infected with influenza 
annually (106). Individuals with chronic medical conditions such as diabetes or heart disease 
are at increased risk of influenza-associated morbidity and mortality (107). 
 
F. Influenza A: Life Cycle 
 Influenza virus, a member of the Orthomyxovirus family, is a single-stranded, 
negative sensed, segmented RNA virus that infects epithelial cells that line the respiratory 
tract (108). Influenza is classified by its surface hemagglutinin (HA) and neuraminidase (25) 
glycoproteins. Infection begins when the viral hemagglutinin (HA) molecule binds to sialic 
acid-containing receptors on the surface of the host cell, and the viral envelope fuses with the 
host cell membrane. Infectivity requires cleavage of HA into disulfide linked products, which 
in the case of Influenza A/PR8, is performed by a ubiquitous set of proteases (109). The virus 
is internalized by clathrin-coated pits and is transported by endosomes where HA-mediated 
fusion of the viral envelope with the endosomal membrane occurs. This fusion is succeeded 
by entry of viral ribonucleoproteins into the nucleus (110).  
 
 In the nucleus, host cellular pre-mRNA is cleaved by an influenza-encoded cap 
dependent endonuclease. This allows for the generation of capped primers followed by 
initiation of viral mRNA synthesis (111).  Viral replication begins after the synthesis of 
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mRNA and requires the formation of viral proteins. Viral progeny are produced from 
complementary RNA that was generated from the parental RNA (112).   
 
 Newly generated vRNAs are exported from the nucleus. This is mediated by the 
interaction of viral nucleoprotein (NP) and matrix protein (M1) (113). The encapsidated 
vRNAs assemble at the plasma membrane where they are packaged into virions. The 
interaction M1 with HA and neuraminidase (25) facilitate concentration of viral components 
and exclusion of host proteins. Virions egress the cell by budding through the plasma 
membrane resulting in viral envelope that is derived from the host cell membrane (114).   
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Figure 1.3. Life Cycle of Influenza Virus (115) 
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G. Immune Response to Influenza Infection 
 Host response to and recovery from influenza virus infection requires an intact innate 
and acquired immune system.  A coordinated pattern of cytokine secretion (116) is 
responsible for inhibiting viral replication (117), stimulating an inflammatory response (118), 
and recruiting immune cells to the site of infection (119). 
 
1. Innate Immune Response 
 The innate immune response is an immediate, relatively non-specific, response to 
pathogen. The purpose of the innate immune system during influenza is to control the spread 
of virus and concomitantly activate a virus specific response. This is done primarily through 
the actions of cytokines and chemokines secreted from virally infected cells  
 
1.1 Respiratory Epithelial Cells 
 Infection of lung epithelial cells with influenza leads to the production of cytokines 
and chemokines that initiate immune responses. Infection of human primary lung bronchiolar 
and alveolar epithelial cell cultures with influenza indicate that these cells produce 
interleukin (IL)-β, IL-6, and regulated on activation, normal T cell expressed and secreted 
(RANTES) in responses to influenza (120).  These cells are also a major source of interferon 
(IFN)-α/β (121). Infected epithelial cells die by necrosis which triggers cytokine production 
and activation of immune responses.  
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1.2 Macrophage  
  Recruitment of monocytes/macrophages into the lung is a hallmark of the innate 
immune response. These cells are fully susceptible to infection, however they die by 
apoptosis before the virus completes one replicative cycle (122). Infected monocytes and 
macrophages contribute to the host response by the transcription and production of pro-
inflammatory cytokines, such as tumor necrosis factor (TNF)-α, IL-1β, IL-6 and IFN-α/β, 
and the chemokines RANTES, monocyte chemotactic protein (MCP)-1 and macrophage 
inflammatory protein (MIP)-1α (123, 124).  The production of these cytokines induces the 
activation and migration of additional blood monocytes, as well as T and B cells to the site of 
infection. In the lung and LN, macrophage present antigen to T cells, this leads to the killing 
of virus-infected cells and initiation antigen specific T cell responses, respectively. 
 
1.3 Dendritic Cells (DC) 
 Dendritic cells (DC) are principal antigen presenting cells and are the initiators and 
modulators of the immune response (125). Like macrophage, DCs can be directly infected 
with influenza, however, they are also very good at viral uptake through macropinocytosis or 
phagocytosis. Endocytosed virus is processed it into peptide fragments which are then 
presented to T cells on the major histocompatibility complexes. Presentation of antigen by 
DCs is far superior than that of macrophage due to their high expression of MHC-peptide 
complexes and co-stimulatory molecules. Antigen  presentation to T cells occurs following 
migration of the dendritic cell to the draining lymph node through which T cells are 
circulating (125). The cytokines produced by DCs during antigen presentation play an 
important role in the activation and polarization of T cell responses. For example, during 
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influenza infection, DCs produce IL-12 which acts as a potent stimulator of Th1 responses 
and also functions directly on CD8+ T cells to augment cytolytic activity and IFNγ 
production (125, 126). Through their production of IFNα/β and IL-12 dendritic cells also 
play a critical role in NK cell expansion and activation (127). 
 
1.4 Natural Killer (NK) Cells 
Natural Killer (NK) cells are cytotoxic lymphocytes that kill virally infected cells. 
The ability of NK cells to recognize virally infected cells relies on a system of recognition by 
their killer-activating receptors and killer-inhibitory receptors. The killer-activating receptors 
recognize molecules present on the surface of all host cells whereas the killer-inhibitory 
receptors recognize MHC class I molecules. All nucleated cells have MHC Class I and thus 
engage the inhibitory receptor on the NK cell to prevent NK cell activation.  Therefore, the 
down regulation of MHC Class I molecules by influenza virus, which can help it evade some 
immune responses, attenuates the signal from the killer-inhibitory receptor and leads to 
activation of NK cell killing (128). 
 
NK cell activity is augmented by IFN α/β and IL-12, the latter also induces IFNγ 
production by the NK cell, which activates antiviral gene expression and increases antigen 
presentation by macrophage (127).  
 
2. Cell-Mediated Immune Responses 
 The cell-mediated, or adaptive, immune response, is the classification given to cells 
that participate in the arm of the immune response that is specific for the invading pathogen. 
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Due to the fact the cell-mediated immune response must be generated de novo and relies on 
“information” from the innate immune response, peak activation of this response occurs days 
after initial antigen insult. During influenza infection, the cell-mediated response is 
characterized predominantly by T cells, which are recruited to the infected lung and eradicate 
virally infected cells.  
 
2.1 Major Histocompatibility Complex (MHC) Molecules 
 For a specific immune response to be generated, antigen must first be presented to 
naïve T cells via major histocompatibility complex (MHC) molecules. These molecules are 
expressed on the surface of cells and function to display both self and non-self antigens. Two 
main classes of MHC exist, Class I and Class II. Class I is present on all nucleated cells and 
presents peptides from cytosolic antigens (128) to T cells with the CD8 receptor. Class II, 
however, is exclusively on antigen presenting cells. This MHC molecule presents antigenic 
peptides generated from lysosomal degradation to T cells with a CD4 receptor.   
 
2.2 T cells 
 T cells mature in the thymus where they become either CD4 or CD8 positive. Single 
positive, naïve, T cells egress from the thymus and circulate through the body.  Circulating T 
cells migrate through peripheral lymphoid tissues, such as the lymph node, where they 
sample MHC-peptide complexes on antigen presenting cells for antigen recognition. This 
sampling increases the probability of the T cell to encounter antigen, which is crucial given 
that one naive T cell in 104-106 is likely to be specific for a particular antigen (129). When 
the T cell receptor (TCR) recognizes antigen an activation signal is transmitted by the CD3 
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complex of molecules on the T cell.  This leads to rapid clonal expansion to produce the large 
numbers of progeny that will differentiate into armed effector T cells. Activation also induces 
synthesis of IL-2, which is produced by the activated T cell and drives clonal expansion and 
differentiation. Therefore one T cell can give rise to thousands of progeny that all have the 
same receptor for antigen (129). 
 
 There are two classes of T cells that are distinguished by the expression of the cell-
surface proteins CD4 and CD8. These two types of T cell differ in the class of MHC 
molecule they recognize; CD4 binds to MHC class II and CD8 binds to MHC class I.  
 
2.2.1 CD4+ T cells 
 Naive CD4+ T cells can differentiate into helper T cells with either a Th1 or Th2 
phenotype. To which helper subtype the CD4+ T cell differentiates depends on the pathogen 
and by the cytokines that are secreting during presentation on MHC Class II. During 
influenza infection, IL-12 secretion by the DC will polarize the CD4+ T cell toward a Th1 
phenotype. This results in IL-2 and IFNγ production by the CD4+ cells which activate CD8+ 
T cells.  Conversely, induction of a Th2 response leads to the secretion of IL-4, IL-5, and IL-
10, which downregulate Th1 responses and promotes B cell activation and antibody 
production. Although CD4+ T cells help promote CD8+ activation during influenza infection, 
it is not required as mice that lack MHC Class II molecules, elicit a normal CD8+ effector T 
cell response (130).  
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2.2.2 CD8+ T cells 
Unlike naïve CD4+ T cells, naive CD8+ T cells are programmed to become cytotoxic 
cells. Proliferating CD8+ T cells gain effector function upon MHC Class I-peptide binding in 
concert with co-activating molecules. During influenza infection, CD8+ T cells traffic from 
the lymph node into the tissue parenchyma, where effector function is critical for appropriate 
clearance of virus.  During an active infection, CD8+ T cells compose almost 70% of the lung 
lavage population, of which, almost 90% are specific for four viral epitopes (131), (132).  
 
Upon encounter with antigen, CD8+ T cells produce IFNγ which will inhibit viral 
replication. Additional elimination of virus infected cells by CD8+ cells occurs through direct 
lysis (133) by two different pathways: perforin/granzyme B or FasL. In the 
perforin/granzyme B pathway, CD8+ T cells insert perforins into the membranes of infected 
cells which is followed by the release granzymes. This activates caspases and results in 
apoptosis. Alternatively, caspase activity can be activated by Fas/FasL interaction.  
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Figure 1.4.  Activation of Th1 response by virus infected macrophage (128) 
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3. Virus Induced Cytokine Signaling 
 
 Infected cells limit viral replication via receptor and cytokine signaling pathways. 
Viral RNA is recognized through various receptors found on cell surfaces and in endosomal 
compartments. Binding of viral components initiates signaling cascades that result in 
cytokine production by infected cells. Cytokines signal primarily through receptors that 
require the Janus kinase/ Signal transducer and activator of transcription (JAK/STAT) to 
activate components of the immune response (Figure 1.5).  
 
3.1 Viral Recognition 
 Influenza viral RNA is recognized through various receptors including; Toll-like 
receptors (TLR 3, 7, and 9), retinoic acid inducible gene I (Rig), and Rig-like receptors (134). 
Binding of viral RNA to these receptors activates separate, but often overlapping, signaling 
pathways which result in the transcriptional activation of Type I IFNs (IFNα/β) via interferon 
regulatory factor (IRF) DNA binding (135). TLR’s also activate NF-κB and MAPK signaling 
pathways which promotes the transcription of cytokines and chemokines (136). Additionally, 
viral nucleic acids activate protein kinases and RNase L which non-specifically block 
translation and degrade RNA, respectively (137, 138) and lead to apoptosis (139).  
 
3.2 Type I Interferons 
 Type I IFN can be produced in all nucleated cells in response to viral infection and all 
cells can respond to them (140). These cytokines act in a positive feedback loop through 
IFNA receptors (IFNAR) activation of STATs 1 and 2 to increase antiviral protein 
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Figure 1.5. Overview of cytokine/receptor signaling pathways (141) 
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expression, increase viral recognition receptors, as well as increase their own expression 
(135). Their importance in immune activation is illustrated by the ability to promote 
differentiation of monocytes to DCs (142), activate NK cells (127), upregulate MHC Class I 
and II expression (143), enhance priming of Th1 cells (144), and induce NF-kB and MAPK 
activation (145, 146).  Their role in IFNγ production by NK cells is mediated through STAT4 
activation (127). The necessity of Type I IFN during influenza infection is unclear, as some 
studies have reported higher viral titers and increased mortality in mice lacking the IFNβ 
gene (147), while others have shown little effect on viral replication or CD8+ T cells 
responses in mice lack IFNAR (148). Type I IFNs are necessary for NK cell cytotoxicity, 
however (127) and general disruption of STAT1 results in extreme susceptibility to infection 
(149).  (See Table 1.3 for list of cytokines/chemokine induced during influenza virus 
infection).  
 
3.3 Type II Interferon 
 IFNγ, Type II IFN, can also promote NF-κB and MAPK activation through synergy 
with TLRs in macrophage (150). Unlike Type I IFNs, which are induced by viral nucleic 
acids, IFNγ is induced by T cell receptor crosslinking, as well as by APC derived cytokines 
TNFα and IL-12, and by autocrine action (151, 152). It mediates numerous antiviral effects 
by STAT 1 induction of IRFs which act as secondary transcription factors and activate genes 
involved in the following: upregulation class II MHC molecules; regulation of leukocyte-
endothelium interaction; polarization of Th1 and suppression of Th2 responses; induction of 
IL-12 and TNFα; and numerous others (153). CD4 T cell secretion of IFNγ is a defining 
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characteristic of the Th1 response and IFNγ is critical for antigen-specific CD8 T cell 
homeostasis during influenza infection (154). 
 
3.4 IL-12 
 IL-12 is produced by DC, macrophage, and neutrophils (155, 156) and signals by 
recruiting STAT3 and 4 to phosphorylated JAK2 on the IL-12R. This mediates IL-12 effector 
functions which includes induction of IFNγ by NK cells (157). Importantly, IL-12 acts in a 
non-redundant way to promote Th1 polarization (158) and is itself induced by IFNγ (159). 
Mice that lack STAT4 have minimal IFNγ production, reduced NK cytotoxicity, and less 
proliferation of activated lymphocytes (158).   
 
3.5 IL-6 
 IL-6 is cytokine that is induced by TLR signaling in macrophage. It signals through a 
gp130 receptor and transduces its effects through JAK/STAT signaling. Macrophage 
production of IL-6 induce antiviral responses through STAT1 activation of IFN-induced 
genes (160), but also inhibits LPS-induced TNFα production through STAT3 (161), thereby 
acting to both induce and repress immune responses. A role for IL-6 in T cell homeostasis 
was shown in T cell specific STAT3 knock out mice.  These mice had reduced T cell 
proliferation due to increased apoptosis which was prevented by IL-6 administration in 
normal cells (162).  
 More recently, it has been proposed that IL-6 contributes to chronic inflammation in 
obese human as serum IL-6 levels correlate with body fat (163). These findings are not 
consistent however (164). Currently it is unclear how low levels of IL-6 affect metabolic or 
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immune function since diet-induced obese rodents do not have increased circulating 
cytokines therefore making it difficult to study experimentally.   
 
3.6 IL-10 
 IL-10 signals through the IL-10 receptor with downstream effects mediated by Jak1 
and STAT3. IL-10 is considered “anti-inflammatory”, hence it suppresses the expression of 
inflammatory genes (162, 165). Overexpression of IL-10 in antigen presenting cells has been 
shown to inhibit clearance of antigen and therefore expression must be tightly regulated 
(166). Conversely, a lack of IL-10 during bacterial infection lead to overactivation of CD4 T 
cells, IL-12, IFNγ, and TNFα (86).  
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Table 1.2 Cytokines and chemokines expressed during influenza virus infection [Adapted 
from (133)] 
 
Chemokine/cytokine Function Produced by 
IFNα/β Inhibit viral replication 
Promote NK cell proliferation and 
cytoxicity 
Activate antigen-specific T cells 
Dendritic cells 
Respiratory epithelium 
   
IFNγ Inhibits viral replication 
Stimulates CTL mediated killing 
Increases MHC I expression 
Activates macrophage and neutrophils 
Promotes T-cell proliferation 
T cells 
NK cells 
   
TNFα Direct antiviral effects 
Neutrophil chemoattractant 
Stimulates macrophage phagocytosis    
and production of IL-1 
Increases vascular permeability 
T cells 
Monocytes/macrophage 
Dendritic cells 
Neutrophils 
   
IL-1 Increases expression of adhesion factors 
on endothelium 
Increases vascular permeability 
Stimulates IL-6 production 
Monocytes/macrophage 
Dendritic cells 
   
IL-6 Pro-inflammatory cytokine 
Activates T cells 
Respiratory epithelium 
T cells 
Monocytes/macrophage 
Dendritic cells 
   
IL-12 Promotes differentiation of naïve T cells 
to Th1 
Enhances cytotoxic activity of NK cells 
and T cells 
Stimulates IFNγ production by dendritic 
cells and NK cells 
Macrophage 
Dendritic cells 
   
MIP-1α/β Monocytes/ T cell chemoattractant 
Activates neutrophils 
Monocytes/macrophage 
Neutrophils 
T cells 
Dendritic cells 
   
RANTES Monocyte/T cell/Dendritic cell 
chemoattractant 
Activates T cells 
T cells 
Respiratory epithelium 
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3.7 Signaling deactivation 
 
 Phosphatases have been shown to play a role in JAK/STAT deactivation. For 
example PTP SHP2, a ubiquitously expressed phosphatase, is recruited to the phosphorylated 
tyrosines on the gp130 receptor where it inhibits receptor signaling (167). SOCS proteins are 
another class of molecules that attenuate cytokine signaling. These are recognized as classic 
feedback inhibitors, acting on the JAK/STAT pathway from which they were induced. SOCS 
1 and 3 bind to the activation loop of JAKs and inhibit phosphorylation of the receptor, 
STAT, and JAK (168), thereby attenuating activation signals from the receptor.  A list of 
SOCS proteins and there target are presented in Table 1.3.  Additional regulation occurs via 
cytokines that act as negative regulators (169).  
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Table 1.3. SOCS proteins and their target molecules (170) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Name Inhibits signaling by: Associates with: 
 
CIS IL-2; IL-3; prolactin; Epo; IGF-1; GH  Epo receptor; IL-3 receptor ; GH receptor; IL-2 
receptor; PCK   
SOCS1 IL-2; IL-3; IL-4; IL-6; GH; prolactin; Epo; 
LIF ; IFN- ; IFN- ; OSM; TSLP; Tpo; 
IGF-1 
JAK1;JAK2; JAK3; Grb2; Vav; FGF receptor; 
PYK2; GH receptor; Kit receptor; Flt3 receptor; 
IGF-1 receptor 
SOCS2 GH; IL-6; LIF; IGF-1; prolactin  IGF-1 receptor; prolactin receptor; GH receptor  
SOCS3 IL-2; IL-3; IL-4; IL-6; GH ; prolactin; Epo; 
LIF; IFN- ; IFN- ; CNTF; leptin; OSM; 
IGF-1; insulin  
Lck; FGF receptor; PYK2; GH receptor; Epo 
receptor; leptin receptor; gp130; IGF-1 receptor  
SOCS4 Not known Not known 
SOCS5 IL-6  Not known 
SOCS6 Not known Not known 
SOCS7 Not known Ash; Nck; PLC   
 
Abbreviations: PKC = protein kinase C; OSM = oncostatin M; Tpo = thrombopoietin; CNTF = ciliary 
neurotrophic factor; TSLP = thymic stromal lymphopoietin 
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  ABSTRACT  
 Obesity is associated with an impaired immune response, an increased susceptibility 
to bacterial infection, and a chronic increase in pro-inflammatory cytokines such as IL-6 and 
TNFα. However, few studies have examined the effect of obesity on the immune response to 
viral infections.  Because infection with influenza is a leading cause of morbidity and 
mortality worldwide, we investigated the effect of obesity on early immune responses to 
influenza virus exposure. Diet-induced obese and lean control C57BL/6 mice were infected 
with influenza A/PR8/34 and lung pathology and immune responses were examined at d 0 
(uninfected), 3, and 6 post infection.  Following infection, diet induced obese mice had a 
significantly higher mortality rate than the lean controls and elevated lung pathology. Anti-
viral and pro-inflammatory cytokine mRNA production in the lungs of the infected mice was 
markedly different between obese and lean mice.  IFNα and β were only minimally expressed 
in the infected lungs of obese mice and there was a notable delay in expression of the pro-
inflammatory cytokines IL-6 and TNFα. Additionally, the obese mice had a substantial 
reduction in NK cell cytotoxicity.  These data indicate that obesity inhibits the ability of the 
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immune system to appropriately respond to influenza infection and suggests obesity may lead 
to increased morbidity and mortality from viral infections.  
 
B.  INTRODUCTION 
 Obesity has been associated with immune dysfunction (24, 171, 172). In humans, 
responses of peripheral lymphocytes to mitogen stimulation are reduced (39). Some studies 
have reported higher T cell counts (173), whereas others report no change (174) or lower T 
cell counts (175), while still others demonstrate changes in the T cell population frequency 
(176). In addition, obese individuals have a low level of circulating TNF-α and IL-6, 
suggesting a state of chronic inflammation. Studies using animal models of obesity, both 
genetic and diet induced, also report immune dysfunction (43, 49, 63). In vitro response to 
mitogens is diminished in obese animals (177) and secretion of IL-4 and IFN-γ is altered 
(51). Because obesity is associated with immune dysfunction, it is plausible that obese mice 
infected with a viral pathogen would be unable to mount an effective immune response. To 
test this hypothesis, we infected lean and diet induced obese mice with influenza virus, a 
serious human pathogen. Studies examining the effect of obesity on infection are minimal 
and to our knowledge, this is the first report on the effect of obesity on an influenza virus 
infection.  
 
 Influenza infection is a major cause of morbidity and mortality worldwide.  Once 
infected, an appropriate coordination of both innate and adaptive immune responses is 
necessary for elimination and recovery from the virus. Groups at high risk for increased 
influenza virus mortality include the elderly, the very young, and individuals with chronic 
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pulmonary and/or cardiovascular conditions (178). Interestingly, obesity is also associated 
with chronic pulmonary and cardiovascular diseases (179, 180). Upon infection with 
influenza virus, dendritic cells, macrophages, and lung epithelial cells upregulate the 
expression of cytokines and chemokines. These molecules play essential roles in the early 
inhibition of viral replication (181), the stimulation of an inflammatory response (118) and 
recruitment of immune cells to the site of infection (119).  Additionally, cytokines activate 
natural killer (NK) cells which are among the first cell types to become mobilized during an 
influenza infection.  NK cells assist in eliminating infected cells and help limit viral spread 
until a specific cell-mediated response can be assembled (182).  The expression of cytokines 
and chemokines during an influenza virus infection occurs in a coordinated and specific 
cascade. Antiviral and pro-inflammatory cytokines are induced first, followed by IL-6 
expression, and finally chemokines, such as monocyte chemotactic protein (MCP)-1 and 
macrophage inflammatory protein (MIP)-1α are expressed (183). Changes in the expression 
of any of these molecules can alter subsequent immune responses (184).   
 
 In this study, we asked whether obesity could affect the early immune response to 
influenza virus infection, and therefore alter viral pathogenesis. We found that diet-induced 
obese mice had a marked increase in mortality compared to lean mice. Furthermore, 
significant alterations in immune function, including alterations in cytokine and chemokine 
profiles and reduced NK cell function, were found in obese mice. These data indicate that 
obesity is a potent mediator of immune responses during influenza infection and, therefore, 
may increase susceptibility to the adverse effects associated with the virus. 
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C.  MATERIALS AND METHODS 
 
Animals 
 Weanling C57BL/6J mice were obtained from Jackson Laboratories (Bar Harbor, 
MA). All mice were housed in the University of North Carolina Animal Facility, which is 
fully accredited by the American Association for Accreditation of Laboratory Animal Care. 
Animals were maintained under protocols approved by the Institutional Animal Use and Care 
Committee.  Mice were randomized to receive either a low fat/no sucrose diet (LF) or a high 
fat/high sucrose (HF) diet for 22 wk. Mice were housed four per cage with free access to 
food and water, with the exception of an 8 h food fast prior to blood draws for glucose and 
insulin measurements as well as NK cell cytotoxicity.  
 
Diets 
 The diets, which have been previously described (185), were obtained from Research 
Diets, Inc. (New Brunswick, NJ). The LF diet (D12328) consisted of 16.4% protein, 73.1% 
carbohydrate (83% starch, 17% maltodextrin), 10.5% fat (38% soybean, 62% coconut oil).  
The HF diet (D12331) consisted of 16.4% protein, 25.5% carbohydrate (51% sucrose, 49% 
maltodextrin), 58% fat (93% coconut oil, 7% soybean oil). 
 
Virus and Infection 
 The mouse adapted strain of Influenza A/Puerto Rico/8/34 (A/PR8) (American Type 
Culture Collection, Manassas, VA) was propagated in the allantoic fluid of fertilized chicken 
eggs and the viral titer was determined by hemagglutination assay (186). After 22 wk on the 
diets, mice were anesthetized with an intramuscular injection of a ketamine 
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(0.6mg/kg)/xylazine (0.35mg/kg) solution and infected intranasally with 0.05 mL of 2 
hemagglutinating units (HAU) of A/PR8 virus diluted in PBS.  Preliminary studies from our 
lab determined that this dose of virus is sufficient to effectively elicit an immune response 
while causing little mortality in infected control mice. 
 
Measurement of blood glucose, serum insulin and leptin 
 To determine if blood glucose and insulin levels were affected by infection, mice 
were fasted for 8 h and blood samples were collected prior to infection  (after 22 wk on the 
diet) and at d 3 and 7 p.i. Blood glucose levels were measured with a Freestyle blood glucose 
monitor (Abbott Laboratories, Abbott Park, IL). Serum insulin was measured by ELISA 
(LINCO Research, St. Charles, MO). Serum leptin was measured by ELISA (R & D 
Systems, Minneapolis, MN) in unfasted mice prior to infection and at d 3 and 6 p.i. 
 
Histopathology of lungs 
 Lungs were removed at d 0, 3, and 6 p.i. and perfused with 4% paraformaldehyde, 
paraffin embedded, cut in 6µm sections and stained with hemotoxylin and eosin (H&E). 
Pathology was graded semi-quantitatively as previously described (187). 
 
Quantitation of viral titers  
 Lung viral titers were determined by a modified Tissue Culture Infections Dose 50 
(TCID50) using hemagglutination as an endpoint, as previously described (188). Briefly, half 
of the right lobe of the lung was removed, weighed, and ground in 150 uL minimal essential 
media. Samples were spun and the supernatant was serially diluted starting at 1:5 in MEM 
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containing 20ug/ml trypsin. Each diluted supernatant (100µL) was added, in duplicate, to 
80% confluent MDCK cells and incubated at 37oC for 72 h. A 0.5% suspension of human O 
RBC (50µL) was added to each well and incubated at room temperature for 2 h. Viral titer 
was expressed as the reciprocal of the highest dilution at which the RBC agglutinated. This 
value was then normalized to total protein in the sample. Total protein was determined by 
bicinchoninic acid assay, as previously described (189). 
 
Quantitation of lung mRNA cytokine levels 
 Half of the right lobe of the lung was removed at d 0 (uninfected), 3, and 6 p.i. Total 
RNA was isolated using the TRIzol method (Invitrogen, Carlsbad, CA).  Reverse 
transcription was carried out using Superscript II First Strand Synthesis kit (Invitrogen) using 
oligo (dT) primers. Levels of mRNA levels for murine IFNα, IFNβ, IFNγ, IL-1β, IL-6, IL-
10, IL-12, TNFα, MCP-1, MIP-1α, regulated upon activation, normal T-cell expressed, and 
secreted (RANTES), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were 
determined using qRT-PCR. Fluorescent reporters were detected using Bio-Rad (Hercules, 
CA) iCycler PCR machine and primers and probes were designed using Primer Express 1.5 
(Applied Biosystems, Foster City, CA). The levels of mRNA for GAPDH were determined 
for all samples and were used to normalize gene expression. All data are expressed as fold 
induction over lean, uninfected controls. There were no statistical differences between lean 
and obese uninfected controls. 
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Enumeration of NK cell populations in the lung and spleen  
 Lungs were removed at d 3 p.i. and incubated in a collagenase solution (1500 
units/set of lungs) for one hour. Both spleen and lung tissue was processed into single cell 
suspensions by mechanical agitation of a Stomacher (Seward, UK) and strained through a 
40µm nylon filter.  Cells were stained with fluorescein (FITC)-labeled anti-DX5 and 
Phycoerythrin (PE)-labeled anti-CD3 (BD Pharmingen, San Diego, CA) and analyzed by 
FACSCaliber.  The lymphocyte population was gated and NK cells were identified as CD3-
DX5+ within that gate. 
 
 
Determination of natural killer cell cytotoxicity 
 To determine if obesity had an effect on the ability of NK cells to lyse a target, 
isolated lung and spleen cells were analyzed in a standard NK cell cytotoxicity assay (190), 
using 51Cr-labeled YAC-1 tumor cells (ATCC) as targets. Briefly, serially dilutions of 0.1 
mL lung or spleen effector cells, starting at 1 x 107 cells/mL, were plated with 1 x 104 cells 
51Cr labeled YAC-1 target cells in a 96-well V-bottom microplate. The resulting effector to 
target (E:T) ratios were 100:1, 50:1, and 25:1. All samples were prepared in triplicate. To 
determine maximum lysis, 0.1mL of 10% sodiumdodecylsulfate was added to labeled YAC-
1 cells. To determine spontaneous release 0.1 mL of the culture media was added to 
radioactive YAC-1 cells. Release of 51Cr content was analyzed using a gamma counter 
(Cobra II, Hewlett Packard) and percent specific lysis was calculated by the following 
equation:  
  % specific lysis =   cpm (sample) – cpm (spontaneous release)     x 100 
    cpm (maximum release) – cpm (spontaneous release) 
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Statistical Analysis 
 Statistical analyses were performed using JMP Statistical Software (SAS Insititute, 
Cary, NC).  Normally distributed data was analyzed by two-way ANOVA with diet and day 
post infection as main effects.  Where appropriate, Student’s t-test was used for post hoc 
analysis α = 0.05. Non-parametric data was analyzed using Kruskal Wallis test, P ≤ 0.05. 
 
D.  RESULTS  
Elevated  insulin levels in obese mice during influenza infection  
 Because diabetes is a risk factor for complications of an influenza infection (191), we 
wanted to determine if mice fed the HF diet had elevated glucose and insulin levels both 
before and during infection. As shown in Figure 2.1A insulin levels at baseline were similar 
between lean and obese mice, but increased during infection in the obese mice. Glucose 
levels were significantly elevated at baseline and at d 3 p.i. in the obese mice, but decreased 
by d 7 p.i to levels similar to lean mice (Figure 2.1B). Conversely, glucose levels in lean 
mice were unaffected by influenza infection. The fact that insulin levels are significantly 
elevated in obese mice during infection suggests that the obese mice developed transient 
insulin resistance during influenza infection. 
 
Obesity reduces serum leptin levels during influenza infection.   
 Previous studies have shown that serum leptin increases in response to infection in 
normal weight mice (6, 99, 192), and given the fact that obesity results in chronically 
elevated leptin levels, we wanted to determine what effect influenza infection had on serum 
leptin levels and if this was altered by obesity. As expected, baseline leptin values were 
higher in obese mice compared to lean mice (Figure 2.1C). Interestingly, leptin responses 
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during infection differed between the two groups. In lean mice, circulating leptin levels 
tended to increase transiently following infection, with the concentration at d 6 p.i. being 
similar to the uninfected levels, but significantly less than at d3 p.i.  On the other hand, obese 
mice had a transient decrease in serum leptin during infection, with levels at d3 p.i. being 
significantly lower than at d 0 or 6 p.i. (Figure 2.1C). 
 
Obesity results in high mortality during influenza infection. 
 As shown in Figure 2.2A, obese mice had a mortality rate that was 8 fold greater than 
lean mice (5.5% in lean versus 42% in obese). The obese mice died at d 8 p.i. 
 
Viral titers and lung pathology are similar between lean and obese mice. 
 The high mortality rate in the obese mice indicated that an influenza virus infection is 
significantly altered by obesity. To determine if the increased mortality was associated with 
an increased viral load in the obese mice, we measured lung viral titers at d 3 and 6 p.i.  As 
shown in Figure 2.2B, viral titers were similar between lean and obese mice at d 3 p.i., 
although by d 6 p.i. the lung virus titer was decreased in the obese mice compare to lean. 
However, viral titers were still high in both groups.  
 
 Lung inflammation is a significant contributor to increased mortality in influenza-
infected mice. To determine if obese mice had significantly elevated lung pathology 
compared to lean mice, we examined lung tissue following infection. Figure 2.2C shows that 
although lung pathology increased in both groups after influenza infection, the obese mice 
tended to have increased lung pathology compared to lean mice (P ≤ 0.1).  These data 
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indicate that although an excessive amount of influenza virus in the lungs was not the cause 
of the high mortality in the obese mice, augmented lung pathology may have contributed to 
the higher mortality rate.   
 
Obese mice have reduced expression of antiviral cytokines.  
 The expression of IFNα and IFNβ is induced by double stranded RNA (193) early 
during infection and these cytokines function to control viral replication. Additionally, they 
act as potent activators of NK cell cytoxicity (127).  As shown in Figure 2.3, lean mice had a 
robust increase in mRNA expression of IFNα and IDNβ at d 3 p.i. unlike obese mice whose 
antiviral cytokine expression remained low throughout the infection.  It is important to point 
out that lung viral titers are equivalent between lean and obese mice at d 3 p.i., suggesting 
that an unequal amount of virus did not cause the difference in IFNα/β expression. 
 
Reduced  NK cytotoxicity in influenza infected obese mice  
 Because IFNα and β were greatly reduced in obese mice, we reasoned that NK cell 
cytoxicity may be impaired in these mice. To determine if NK cell activity was affected by 
obesity, we measured lung and splenic NK cell cytotoxicity both prior to and three days after 
infection. NK cell cytoxicity prior to infection was low in both lean and obese mice, with 
cytotoxicty in the spleen being less than 10%, and in the lungs, cytotoxicity was below the 
detection limit of the assay (data not shown). However, during infection, obese mice had 
significant reductions in NK cell mediated killing compared to lean mice. As shown in 
Figure 2.4A, lung NK cell cytotoxicity was reduced by more than 50% in obese mice at d 3 
p.i. This reduction may be due, in part, to the decreased proportion of NK cells in the lungs 
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of obese mice. As shown in Figure 4B, the proportion of NK cells in the lungs of obese mice 
was 22% whereas NK cells made up 30% of the lung lymphocyte population in lean mice.  
Analogous to the lungs, NK cell killing in the spleens of obese mice was also dramatically 
reduced (Figure 2.4C). However, unlike the lung, this was not due to a difference in NK cell 
frequency, because the percentage of splenic DX5+CD3- cells were equivalent between lean 
and obese mice (Figure 2.4D). 
 
 Since NK cell cytotoxicity can be affected by other cytokines, we also measured the 
mRNA expression of IL-12 and IL-18 which are known to enhance NK cell cytotoxicity 
(194, 195). Although IL-12 mRNA levels were not different between lean and obese mice, 
IL-18 mRNA levels were significantly lower in obese mice post infection (Figure 2.4E and 
2.4F), suggesting a role for IL-18 in the decreased cytotoxicity of NK cells in obese mice.  
 
Lung mRNA expression of pro-inflammatory cytokines and the anti-inflammatory 
cytokine IL-10.   
 In addition to antiviral cytokine responses and NK cells, inflammatory responses are 
a key part of the innate immune response to influenza infection. Paradoxically, they can also 
contribute to lung pathology due to increased inflammatory infiltrate.  We examined gene 
expression of the pro-inflammatory cytokines IL-6, TNFα, and IL-1β in the lungs of obese 
and lean mice.  As shown in Figure 2.5, lung mRNA expression at d 3 p.i. for all three 
cytokines was significantly lower in obese mice. Interestingly, the expression of TNFα and 
IL-6 was down regulated by d 6 p.i. in lean mice, whereas obesity led to enhanced expression 
at this time point. These data suggest that during an influenza infection, obesity causes a 
delay in the pro-inflammatory cytokine response. 
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 To determine if the differences in pro-inflammatory cytokine expression at d 3 p.i. 
could be attributed to upregulation of IL-10, a cytokine that counteracts the pro-inflammatory 
effect, we measured its expression in the lungs of obese and lean mice. Similar to the pro-
inflammatory cytokines, IL-10 mRNA levels were significantly lower in the obese mice at d 
3 p.i. compared to the lean mice (Figure 2.5). Unlike IL-6, however, there was no significant 
increase in the expression of IL-10 at d 6 p.i., indicating that the lungs of obese mice were in 
a pro-inflammatory state 6 d after the initial infection. 
 
Decreased lung MCP-1 and RANTES  mRNA expression in influenza infected obese 
mice. 
 The induction of chemokines is an important component of infection with influenza 
virus because they function as attractants for immune cells at the site of infection (184).  As 
shown in Figure 2.6, lung mRNA expression of MCP-1 and RANTES was significantly 
decreased in obese mice 3 d post influenza infection. However, there was no difference in the 
expression of MIP-1α between lean and obese mice, indicating that obesity may cause 
selective recruitment of immune cells to the site of infection. 
 
D. DISCUSSION 
 Although there are reports of genetically obese mice (ob/ob or db/db) having 
impaired immune function (38, 63), there are few studies that have looked at the effect of 
diet-induced obesity on immune function. Diet-induced obesity is a more physiologically 
relevant model of human obesity, as only a small number of individuals are obese due to 
mutations in the leptin gene (196).  Furthermore, there are no reported studies on the effect of 
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diet induced obesity on infection with influenza virus. With over 30% of the population in 
the U.S. obese, and influenza virus infecting 5-20% of the entire U.S. population each year, it 
is important to understand how obesity may impact the host’s ability to respond to infection 
with influenza virus.   
 
 In our study, diet-induced obese mice had an 8-fold higher mortality rate post-
infection. Along with the increase in mortality was an altered immune response, including 
diminished NK cell cytotoxicity and delayed pro-inflammatory cytokine expression. To our 
knowledge, this is the first report of obesity interfering with normal host responses to 
influenza infection.  
 
 It is well established that leptin levels in diet-induced obese mice are higher 
compared to mice of normal weight (61). This chronic elevation, however, appears to cause a 
state of leptin resistance (77, 197), which may be disadvantageous given that numerous 
studies have demonstrated a significant role for leptin in the immune response (6, 63, 198). 
For example, when wild type mice were infected with Klebsiella pnuemoniae, leptin levels 
increased in the blood and lung homogenate and these mice had a normal survival time 
following infection. Conversely, when mice lacking leptin were infected, there was no rise in 
leptin levels following infection and these mice had reduced macrophage function as well as 
a considerably high mortality rate (63). Therefore, we measured circulating leptin levels in 
influenza infected lean and obese mice. We found that leptin levels in lean mice transiently 
increased during influenza infection. Surprisingly, in obese mice serum leptin decreased 
significantly during infection. The cause for this reduction is unknown, but given that the 
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infection was more detrimental to obese mice than lean, the obese group may have stopped 
eating. Limited food intake will result in lower serum leptin levels (6, 199).  This decrease in 
food intake may also have occurred in the lean mice given the high levels of IL-1β and 
TNFα. However, in addition to their anorectic effects, these cytokines increase leptin 
production (200, 201), therefore leptin levels in the lean mice may have been appropriately 
balanced.   
 
Given leptin’s influence on immune function, the reduction in leptin may have 
impaired the innate immune responses in the obese mice. However, it should be noted that 
although the obese mice had a drop in leptin at d 3 p.i., the concentration of serum leptin at 
this time was similar to lean mice. Therefore, if obese mice were still sensitive to leptin, this 
level should be sufficient to generate a response. Usually during an infection, leptin’s effects 
on the innate immune system are generally thought to increase an inflammatory response. 
Leptin acts on macrophages and DCs and augments their production of the pro-inflammatory 
cytokines IL-1β, TNFα and IL-6 (99). In our study, we found that obesity resulted in a 
notable delay in lung pro-inflammatory cytokine expression; obese mice did not significantly 
upregulate these cytokines until d 6 p.i., whereas the lean mice had the expected peak 
expression at d 3 p.i. Given the lack of an early pro-inflammatory response in obese mice, it 
is plausible that leukocytes from the obese mice no longer respond to leptin.  Evidence for 
this comes from a recent report by Papathanassoglou et. al. who demonstrated that signal 
transducer and activator of transcription 3 (STAT3) nuclear translocation is attenuated in T 
cells from obese mice following leptin stimulation. A leptin concentration of 10ng/mL 
caused a five fold change in STAT3 DNA binding in T cells from lean mice, whereas no 
 48 
change was observed from cells taken from the obese mice (77). This study clearly shows 
obesity can cause T cells to become insensitive to leptin and suggests that other cells of the 
immune system would be similarly affected. 
 
An alternative explanation for the reduced early cytokine expression in obese mice is 
a reduction in number and/or maturation of macrophages in the lungs during infection.  Work 
by Krishnan et al. demonstrated that obese humans have similar numbers of circulating 
monocytes, but the number of monocytes that matured into macrophages was almost three 
times less in these individuals (171). Moreover, the ability of a mature macrophage to elicit 
an anti-microbial and cytotoxic response may be inhibited, as Cousin et al. showed an 
impairment in these functions in thioglycollate elicited macrophages from ob/ob mice (202).  
Because macrophages are a major contributor to pro-inflammatory cytokine production, 
fewer macrophages in the lungs, as well as a decrease in their functional capacity, could 
explain the reduction in cytokine levels. It is of note, however, that infiltration of monocytes 
may also be reduced in the obese mice as they expressed significantly lower levels of MCP-1 
at d 3 p.i.  
 
Despite the early lack of induction of inflammatory genes in obese mice, expression 
of IL-6 and TNFα did increase by d6 p.i. to levels comparable to what lean mice expressed at 
d 3 p.i. This late response may be due to increased numbers of infected lung cells and 
infiltration of cytokine producing T cells into the lung. Importantly, the late rise in 
inflammatory gene expression was not balanced by a concomitant rise in IL-10 expression, 
indicating that the lungs of obese mice were in a heightened pro-inflammatory state. Indeed, 
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lung pathology tended to be more severe in obese mice, and it is likely that the upsurge in 
cellular infiltrate was due to this high level of inflammatory gene expression. Furthermore, 
because T cells contribute significantly to lung pathology and peak T cell responses do not 
occur until 8-10 d after the initial influenza infection (203), it is possible that lung pathology 
continued to escalate after d 6 p.i. and resulted in the death of the obese mice.  
 
 In addition to dysregulation of pro-inflammatory mediators, obesity resulted in the 
impairment of other important components of the early immune response.  The induction of 
the antiviral cytokine response, induced primarily by viral factors, was severely blunted in 
obese mice despite equivalent lung viral titers. The lack of IFNα/β expression in obese mice 
indicates that obesity interferes with induction of mRNA expression of these cytokines. This 
may be due to impaired janus kinases (JAK)/STAT signaling caused by an elevation in 
suppressor of cytokine signaling (SOCS) proteins in obese mice. SOCS proteins are activated 
by cytokines signaling through JAK/STAT pathways and function as negative regulators of 
the pathways. However in obese animals, these suppressor proteins are persistently elevated 
(204, 205). Specifically, SOCS1 and 3 are amplified in obese animals and these proteins 
inhibit signaling by type I interferons (206, 207). Since IFNα/β upregulate their own 
expression (181), it is possible the lack of induction of these cytokines is due to impediment 
of the signal.  
 
Because IFNα/β are required for NK cell proliferation and cytotoxicity (127), a 
deficiency in NK activity may have resulted as a consequence of reduced expression of these 
cytokines. NK cells are among the first cells to respond to viral infection and together with 
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type I interferons (INFα/β), provide an innate defense against infection (208). In response to 
intranasal infection with influenza A virus, C57BL/6 NK activity peaks within 3-4 d in the 
spleen, lung, and draining lymph nodes (209-211).  In the current study, obese mice had over 
a 50% reduction in lung and splenic NK cell activity at d 3 p.i. The reduction of NK activity 
in the obese mice is in agreement with previous studies showing that NK cell function is 
decreased in rats fed a high fat diet (212, 213). This reduction in activity may be caused by a 
decrease in cellular arachidonic acid (AA), as splenic lymphocytes from rats fed diets high in 
saturated fat, show reduced levels of AA (212). AA plays an important role in the cytolytic 
activity of NK cells, likely through the production of leukotriene B4 (214, 215). Thus, the 
reduced cytotoxicity of NK cells in obese mice may be a result of a change in splenocyte 
fatty acid composition, leading to an impaired immune response.  
 
Additionally, since obese mice had a lower proportion of NK cells in their lungs, the 
reduction in lung cytoxicity may also be the result of impaired NK cell recruitment to the site 
of infection. Previous studies have shown that MCP-1 and RANTES are important in NK cell 
recruitment (216), therefore the reduced expression of these cytokines in the lungs of obese 
mice may be responsible for the decreased proportion of NK cells. 
 
The importance of the current findings is underscored by the fact that millions 
worldwide are affected by influenza infection every year and the universal prevalence of 
obesity has reached epidemic proportions. In this study, we found that obesity led to 
dysregulated innate immune responses to influenza infection and increased mortality. 
Because the innate immune response also activates and polarizes the appropriate cell 
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mediated response, these data indicate that overall immune function may be affected by 
obesity. Furthermore, these data suggest that in addition to influenza infection, obesity may 
increase susceptibility to other viral infections by way of immune system dysregulation.  
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Figure 2.1. Blood glucose and serum insulin and leptin levels in influenza infected obese and 
lean mice. Following an 8h fast (2400 to 0800), serum insulin (A) and blood glucose (B) was 
measured at 0 (uninfected), 3, and 7 day p.i. (C) Serum leptin was measured in fed mice at 
days 0 (uninfected), 3, and 6 p.i. Values are expressed as mean ± SEM (n=6-8). *, p< 0.05 
vs. lean, #p< 0.05. 
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Figure 2.2. Effect of influenza virus infection on mortality, viral titers, and lung pathology. 
(A) Percent survival was calculated based on the mice remaining in the experiment at day 8 
p.i., as mice were sacrificed at day 0, 3, and 6 p.i. for the experiment. (B) To measure viral 
titers, lungs were removed from mice at day 0 (uninfected), 3, and 6 post-infection and 
homogenized. Supernatants were serially diluted and added to MDCK cells and incubated for 
72 h. Human O red blood cells were added to each well and viral titer was expressed as the 
reciprocal of the lowest dilution at which the RBCs agglutinated. This value was then 
normalized to total protein in the sample and is expressed as the mean normalized titer ± 
SEM (n = 6-8). (C) Lung pathology was scored following blinded examination of 
hemotoxylin-eosin stained sections of paraffin embedded lungs at day 0, 3, and 6 p.i. 
Pathology was scored semi-quantitatively on a scale ranging from 0-4. Values are shown as 
mean ± SEM (n = 6-8). *, p<0.05 vs. lean,  #, p<0.05 vs. baseline. 
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Figure 2.3. Lung mRNA expression of antiviral cytokines. The mRNA expression of 
antiviral cytokines IFNα and IFNβ was quantified by real-time PCR using total RNA 
extracted from lungs of 6-8 mice per group for days 0, 3, and 6 p.i. Values are normalized to 
GAPDH and are expressed as mean fold increase ± SEM over lean, uninfected controls. *, 
p<0.05 vs lean mice 
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Figure 2.4. NK cell cytotoxicity and lung mRNA expression. (A and C) At day 3 p.i. 
isolated spleen and lung cells were analyzed in a standard NK cell cytotoxicity assay, using 
51Cr-labeled YAC-1 tumor cells as targets. The resulting effector to target (E:T) ratios were 
100:1, 50:1, and 25:1. Data are shown as mean ± SEM (n=6-8). *, P≤ 0.01 vs. lean mice, **, 
P≤0.00001 vs lean mice. (B and D) To enumerate NK cells and determine their frequency in 
the lymphocyte population, cells were stained with FITC-labeled anti-DX5 and PE-labeled 
anti-CD3 and analyzed by flow cytometry.  The lymphocyte population was gated and NK 
cells were identified as CD3-DX5+. Data are shown as mean ± SEM (n=6-8). (E and F) IL-
12 (p40) and IL-18 mRNA expression was determined by real time PCR from total lung 
RNA. Lungs were removed from 6-8 mice at day 0, 3, and 6 p.i. mRNA was normalized to 
GAPDH and values are expressed as mean fold increase over uninfected, lean controls ± 
SEM. #P<0.05 vs lean mice. 
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Figure 2.5. Pro-inflammatory cytokine expression in influenza infected lungs from lean and 
obese mice. Lung mRNA expression of cytokines IL-6, TNFα, IL-1β, and IL-10 were 
quantified by real-time PCR using total RNA extracted from lungs at days 0, 3, and 6 p.i. 
Values are normalized to GAPDH and are expressed as mean fold increase ± SEM over lean, 
uninfected controls (n=6-8). *, p<0.05 vs lean mice. 
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Figure 2.6. Lung mRNA expression of chemokines in influenza infected lean and obese 
C57BL/6 mice. The mRNA expressions of chemokines MCP-1, RANTES, and MIP-1α were 
quantified by real-time PCR using total RNA extracted from lungs of 6-8 mice per group for 
days 0, 3, and 6 p.i. Values are normalized to GAPDH and are expressed as mean fold 
increase ± SEM over lean, uninfected controls. *, p<0.05 vs lean mice. 
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A.  ABSTRACT   
 
 There is a clear link between obesity and metabolic disorders, however little is known 
about obesity’s effect on immune function, particularly during an infection. We have 
previously reported that diet-induced obese mice are more susceptible to morbidity and 
mortality during influenza infection than lean mice. Obese mice displayed aberrant innate 
immune responses characterized by minimal induction of IFNα/β, delayed expression of pro-
inflammatory cytokines and chemokines, and impaired natural cell cytotoxicity. To explore 
the cause of this, we analyzed the cell populations in the lungs of lean and diet-induced obese 
mice. We found delayed mononuclear cell entry with a noted decrease in dendritic cells (DC) 
throughout the infection. Given the critical role of the DC in activating the cell-mediated 
immune response, we analyzed the functional capacity of DC from obese mice. We found 
that while obesity does not interfere with antigen uptake and migration, it does impair DC 
antigen presentation. This is likely due to an altered cytokine milieu, as IL-2, IL-12, and IL-6 
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were differentially regulated in the obese mice.  Overall, this did not impact the total number 
of virus-specific CD8+ T cells that were elicited, but did affect the number and frequency of 
CD3+ and CD8+ T cells in the lung. Thus, obesity interferes with cellular responses during 
influenza infection, leading to alterations in the T cell population that ultimately may be 
detrimental to the host.   
 
B.  INTRODUCTION  
 Obesity is clearly associated with metabolic disturbances, such as insulin resistance 
and non-alcoholic fatty liver disease (217, 218). What is less well studied is the impact of 
obesity on immune function. In humans, obesity has been shown to be a risk factor for 
infections, poor wound healing (23, 25), and decreased response to vaccination (219, 220). 
Additionally, obese individual have changes in the circulating T cell population, displaying 
an increased frequency of CD4+, but reduced frequency of CD8+ T cells (176) and 
diminished bacterial killing capacity of polymorphonuclear cells (39).  Studies in genetically 
obese mice demonstrate decreased resistance to infections (38, 221) as well as reduced cell 
mediated cytotoxicity (46, 202). Diet-induced obese mice (DIO) have shown impaired 
antigen presentation (53), as well as altered mitogen-stimulated proliferation of splenocytes 
(51), and diminished NK cell function (49). 
 
 During infection with influenza virus, dendritic cells (DC) and macrophages are the 
initiators and modulators of the immune response (125). DC, in particular, are efficient at 
endocytosing viral antigen and processing it into peptide fragments which are then presented 
on major histocompatibility complexes (MHC). Presentation of antigen by the DC to T cells 
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occurs following migration of the DC to the draining lymph node (LN) through which T cells 
are circulating (125).  This function is performed primarily by conventional DC (cDC), 
whereas plasmacytoid DC (pDC) have limited antigen presenting capacity, but secrete high 
levels of IFNα in the inflamed tissue (222, 223). Both DC subtypes reside in peripheral 
tissues in an immature state and mature after exposure to inflammatory stimuli, but high 
expression of B220 on pDC allows them to be differentiated from cDC.  
 
 In our previous study (224) we demonstrated that diet-induced obese mice infected 
with influenza virus had increased morbidity and mortality. The immune response in the 
obese mice was characterized by minimal expression of Type I inteferons (IFN) and delayed 
expression of pro-inflammatory cytokines and chemokines. These results suggested that 
obese mice have improper recruitment of mononuclear cells to the influenza-infected lungs 
and therefore activation of ensuing responses may be impaired.  
 
 In this paper we demonstrate that recruitment of mononuclear cells to the lung during 
influenza infection is delayed in DIO mice, and the number of DC remains significantly 
lower throughout infection. Despite this, DC were capable of taking up antigen and migrating 
to the LN, but their ability to present antigen to T cells is impaired. As a result, the total 
number of CD8 T cells is reduced in obese mice, but they are capable of eliciting a 
quantitatively normal virus-specific CD8 T cell response.  
 
C.  MATERIALS AND METHODS 
Animals 
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 Weanling C57BL/6J mice were obtained from Jackson Laboratories. All mice were 
housed in the University of North Carolina Animal Facility, which is fully accredited by the 
American Association for Accreditation of Laboratory Animal Care. Animals were 
maintained under protocols approved by the Institutional Animal Use and Care Committee.  
Mice were randomized to receive either a low fat/no sucrose diet or a high fat/high sucrose 
diet for 22 wk. Mice were housed four per cage with free access to food and water. 
 
Diets 
 The diets, which have been previously described (185), were obtained from Research 
Diets, Inc.  
 
Virus and Infection 
 The mouse adapted strain of Influenza A/Puerto Rico/8/34 (A/PR8) (American Type 
Culture Collection) was propagated in the allantoic fluid of fertilized chicken eggs and the 
viral titer was determined by standard plaque assay on MDCK cells. After 22 wk on the diets, 
mice were anesthetized with an intramuscular injection of a ketamine (0.6mg/kg)/xylazine 
(0.35mg/kg) solution and infected intranasally with 0.05 mL of 50 plaque forming units (pfu) 
of A/PR8 virus diluted in PBS.   
 
Lung cell isolation and staining for flow cytometry 
 Lungs were removed, incubated in collagenase solution, then processed into single 
cell suspensions by mechanical agitation of a Stomacher and strained through a 40µm nylon 
filter. Cells were subjected to RBC lysis using ACK lysis buffer for 5 min at room 
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temperature, washed, and counted. At least 5 x 105 cells were stained with fluorescein 
(FITC)- anti-CD11b, allophycocyanin (APC)-anti-CD11c,  phycoerythrin (PE) Cy7- anti-
B220 (eBiosciences) and peridinin-chlorophyll (PerCp)-anti-CD8  and analyzed by 
FACSCaliber. Intracellular staining was performed on total lung cells from influenza infected 
mice that were incubated for 4-6 h with Brefaldin A (BD Biosciences). Cells were then Fc 
blocked with anti-FcγII/III, surface stained, and permeabilized for IL-6 staining.  PE-goat-
anti-mouse-IgG (Sigma) was used as a staining control, and non-specific staining was 
subtracted from the values presented. Antibodies were obtained from BD Biosciences unless 
otherwise noted.  Gates were set for alveolar macrophage (AM), DC, and monocytes based 
on previous reports (225, 226). cDC and pDC were identified from the gated DC population 
as CD11c+B220- and CD11c+B220+, respectively. 
 
FITC uptake and DC migration to lymph node 
 Anesthetized mice were given 250 µg FITC-ovalbumin (OVA) (Molecular Probes) 
intranasally in 50 µl PBS. Control mice were given unconjugated ovalbumin which served as 
gating control for FITC-OVA+ cells.  Mediastinal lymph nodes (LN) were harvested 24 h 
later and processed into single cell suspensions as described above. Prior to filtering and 
RBC lysis, cells were resuspended in calcium and magnesium free HBSS containing 10mM 
EDTA and incubated at room temperature with agitation for 5 min. 1 x 105 cells were stained 
in FACS-EDTA (227) buffer using the antibodies already described and analyzed by 
FACSCalibur. DC were identified by CD11c expression.  
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Quantitation of LN mRNA cytokine levels 
 Total RNA was isolated from the LN at various d p.i. using the TRIzol method 
(Invitrogen).  Reverse transcription was carried out using Superscript II First Strand 
Synthesis kit (Invitrogen) using oligo (dT) primers. Levels of mRNA levels for murine IL-2, 
IL-12 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were determined using 
qRT-PCR. Fluorescent reporters were detected using Bio-Rad iCycler PCR machine and 
primers and probes were designed using Primer Express 1.5 (Applied Biosystems). The 
levels of mRNA for GAPDH were determined for all samples and were used to normalize 
gene expression. All data are expressed as fold induction over lean, controls at d 3 p.i.  
 
Antigen presentation assay 
 Spleens from uninfected mice were removed and processed into single cell 
suspensions by mechanical agitation as described above and pooled (n = 4-5 mice/group). To 
isolate as many DC as possible, cells suspensions were treated with EDTA in a similar 
manner that was described in the FITC-OVA experiment. Cells were then counted and 1 x 
108 cells were used to isolate DC using the DC enrichment kit from Dynal. The purity of the 
CD11c+ population was assessed by flow cytometry and found to be 76% pure. About 20% 
of the population was composed of CD11c-B220+ cells, likely B cells (228), which have 
been shown to be poor stimulators of T cells when antigen is not continuously present in the 
stimulation culture (229). 
 
 T cells were isolated from spleens of lean mice that had been infected with influenza 
7 d prior. Single cell suspensions were incubated on plastic for 1 h and nonadherent cells 
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were collected. This population was shown to be greater than 92% pure by FACS analysis of 
CD3+ cells.  
 
 DC were incubated at an MOI of 2 with 56oC heat-inactivated influenza A/PR8 for 2 
h followed by extensive washing to remove any excess virus. Serial dilutions of 0.1 mL DC, 
starting at 1 x 106 cells/mL, were plated with 1 x 105 T cells in a 96-well round-bottom 
microplate. The resulting DC to T cell ratios were 1:1, 1:2, and 1:4. All samples were 
prepared in triplicate and incubated for 2 h at 37oC, followed by the addition of Golgi Plug 
(BD Biosciences) and incubation for an additional 4 h. Prior to surface staining, Fc receptors 
were blocked with anti-FcγII/III.  Cells were then stained with FITC-anti-CD3, APC-anti-
CD5, PerCp-anti-CD8 (BD Biosciences), followed by fixation and permeabilization for 
subsequent intracellular staining with PE-anti-IFNγ. PE-goat-anti-mouse-IgG (Sigma) was 
used as a staining control.  
 
Tetramer staining for antigen-specific T cells analysis 
 Lungs were removed and processed as described above into single cell suspensions. 1 
x 106 cells were used for staining. Cells were Fc blocked, then stained with the DbNP366-PE 
(ASNENMETM) tetramer, FITC-anti-CD3, APC-anti-CD4, PerCp-anti-CD8 for 45 min at 
4oC and analyzed by flow cytometry. Uninfected mice were used as a staining control and the 
percent nonspecific binding was subtracted from values obtained from infected mice. 
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ELISPOT (Enzyme-Linked Immunosorbent Spot) 
 Lungs were lavaged three times with PBS 7 d after infection to obtain bronchoaveolar 
lavage fluid (BALF). RBC were lysed, cells were counted, and Lyt-2+ CD8+ T cells were 
isolated by positive selection using magnetic beads (Dynal Biotech), according to the 
manufacturers directions. Ninety-six–well filtration plates were coated with capture 
antimouse IFN-γ mAb, washed, and blocked according to the manufacturer's protocol (BD 
Biosciences). Mitomycin C treated splenocytes, infected with Influenza A/PR8, were used as 
antigen presenting cells and 1 × 105 cells were added to wells in duplicate. Isolated lung 
CD8+ cells were added to each well at a concentration of 1 × 104.  Plates were incubated for 
12 hours at 37°C in 5% CO2. Splenocytes alone served as negative controls. After washing 
with PBS/0.1% Tween 20, a biotinylated IFN-γ mAb was added, followed by streptavidin-
alkaline phosphatase. The developed spots were then counted manually. 
 
 Statistics 
 Statistical analyses were performed using JMP Statistical Software (SAS Insititute).  
All results are expressed as mean ± SEM. Statistical significance was calculated using 
Tukey-Kramer HSD or Wilcoxon signed ranks test, α= 0.05 and P < 0.05, respectively. 
 
D.  RESULTS 
Reduced cellularity in influenza infected lungs of obese mice. 
 Previous work from our lab indicated that innate immune responses were dyregulated 
during influenza infection in diet-induced obese mice. We observed minimal Type I IFN 
expression as well as a delay in IL-6 production in obese mice. To determine the reason for 
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this impairment, we infected lean and obese mice and analyzed the cellularity of the lung at d 
0, 3, and 6 p.i. Lung populations were identified by their CD11b and CD11c expression, as 
previously described (225, 230) (Figure 3.1). As expected the total number of cells in the 
lungs of lean mice increased during infection due to mononuclear cell infiltrate (Table 3.1). 
However, the progressive infiltration of mononuclear cells was not observed in obese mice 
until d 6 p.i. While the number of monocytes and DC double by day 3 p.i. and continue to 
increase through d 6 in lean mice, there is little change in these cell populations in obese 
mice until d 6 p.i., yet the number of DC remains significantly lower. Additionally, the 
population of cells not expressing CD11c or CD11b, which likely includes naïve T cells 
(231) and epithelial cells (232)was similar between then groups at d 0 and 3, but was 
significantly lower in obese mice at d 6 p.i. These data indicate that the temporal infiltration 
of monocytes and lymphocytes during influenza infection is affected by obesity, and 
therefore may result in impairment of succeeding responses.   
 
Enhanced IL-6 production by mononuclear cells of obese mice. 
 Given the difference in lung cellularity, we determined if the delay in IL-6 production 
previously observed was due to the reduction in cell number or to an inability of the 
mononuclear cells to produce IL-6. As shown in Figure 3.2A, the total number of IL-6+ cells 
was significantly reduced at day 3 p.i. in obese mice. Interestingly, the reason for this 
reduction appears to be solely due to the decrease in cell number. When the leukocyte 
populations were analyzed for IL-6 production, AM and monocytes from lungs of obese mice 
were found to have a higher proportion of IL-6+ cells (Figure 3.2B). Furthermore, the amount 
IL-6 produced by the AM and monocytes from obese mice was also greater (AM: lean MFI = 
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50.9 ± 1.7 vs obese MFI = 58.9± 1.2, monocyte: lean MFI = 40 ± 0.9 vs obese MFI = 44.2 ± 
0.8, P < 0.05) By day 6, cells from both lean and obese mice produce high levels of IL-6 
(AM: lean MFI = 106 ± 24.8 vs obese MFI = 68 ± 6.7, monocyte: lean MFI = 196 ± 45 vs 
obese MFI = 182 ± 45) and the total number of IL-6+ cells was equivalent (Figure 2A). These 
data indicate that while mononuclear cells are slower to enter the lungs of obese mice 
following infection, resident cells may be hyper-activated early after infection in obese mice.   
 
Obese mice have less lung migrating DC during infection 
 DC are a critical link between the innate and cell-mediated immune responses. There 
are several distinct subsets of DC including cDC and plasmacytoid pDC. Belz et. al. have 
demonstrated there are other major subsets within the cDC population which include the 
CD8-B220-CD11c+ cells (DN). These cells appear to play a major role in antigen uptake in 
the lungs and subsequent migration to the LN. Within the LN, migrating DN cells can 
present antigen to T cells, as well as transfer antigen to LN resident DCs (CD8+B220-
CD11c+) for additional presentation (223).  Since the total number of DCs remained 
significantly lower in obese mice throughout infection, we hypothesized that the number of 
DN DCs would also be lower, thus indicating that obese mice may have reduced antigen 
trafficking to the LN. Therefore we determined the number of DN cells in the lungs of lean 
and obese mice prior to and during infection. Prior to infection we found no difference in the 
number of resident DN DCs between lean and obese mice (Figure 3.3A). By day 3 p.i. 
however, the total number of DN DCs was less in obese mice and this was not simply due to 
a reduction in total DC cell number as the percent of DN cells in the DC population was also 
significantly lower in obese mice at d 3 p.i. (Figure 3.3B). This suggests that infiltration of 
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new DN DCs does not occur in obese mice early during infection which could lead to 
reduced antigen accumulation in the LN. In contrast to the DN DC population, the percent of 
pDC (CD11c+ B220+) during infection was greater in obese mice compared to lean mice 
(Figure 3.3B). Despite the amplified increase in the percent pDCs, obese mice had 
significantly less total pDCs in their lungs at day 3 p.i. than lean mice, though the total 
number remained low in both groups (Figure 3.3C).  
 
DC accumulate in the LNs of obese mice following OVA instillation 
 To determine if DC transport antigen normally in obese mice we instilled FITC-OVA 
intranasally and measured accumulation of FITC+ in CD11c+ cells in LN after 24h.  
Surprisingly, we found that the total number of CD11c+ cells was higher in LN from obese 
mice (Figure 3.4A). With the increase in the total number of DCs we expected to see more 
antigen in the LNs of obese mice. However, we found that obese mice had an equivalent 
number of FITC+ DCs as lean mice (Figure 3.4A). Accordingly, the percent of the DC 
population that contained FITC+ was less in obese mice (Figure 3.4B).  
 
 Since the proportion of lung DN DC decreased following infection in obese mice 
(Figure 3.2B), it was possible that more DN cells had phagocytosed antigen and migrated to 
the LN soon after infection. We determined if this was the case after FITC-OVA instillation. 
When we analyzed the population of DC in the LN we found more DN DC in obese mice 
(Figure 3.4C), though the proportion that made up the DC population was similar between 
the groups (data not shown). In addition, the number of DN DC that contained FITC was 
greater in obese mice.  In both groups a significant proportion of the DN DC were FITC- 
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(Figure 3.4D). These data indicate that DC in obese mice are fully capable of migrating to the 
LN following antigen uptake.  
 
Impaired antigen presentation by DC from obese mice 
 The capacity of the DC to stimulate the appropriate antigen-specific T cell responses 
relies, not only on its ability to migrate to the LN following antigen uptake, but to present 
antigen in conjunction with the production of polarizing cytokines such as IL-12 (233). We 
observed decreased IL-12 expression in LN from obese during influenza infection (Figure 
3.5A).  The initial onset of T cell proliferation during influenza A/PR8 infection begins 
around d 3 p.i. (234) and thus the reduction of IL-12 expression at d 3 p.i. in the LN 
suggested that DC stimulation of CD8+ T cells in obese mice was impaired, despite efficient 
migration to the LN. 
 
 To address whether DC from obese mice were able to stimulate T cells , we 
negatively selected CD11c+ cells from spleens of uninfected lean and obese mice and 
stimulated T cells derived from spleens of influenza-primed lean mice. Infection of DC with 
heat-inactivated influenza has been shown to effectively induce DC maturation and 
subsequent stimulation of T cell proliferation, since the virus retains fusogenic capacity but is 
nonreplicative (235). IFNγ production by CD8+ T cells was used to determine the 
effectiveness of the DC to present antigen.  As shown in Figure 3.5B, influenza pulsed DC 
from lean mice effectively present antigen to CD8+ T cells and elicit an IFNγ response. 
However, there is a 30% reduction in the proportion of CD8+ T cells that produce IFNγ from 
obese mice when DC are present at a 1:1 or 1:2 ratio to T cells. Representative flow 
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cytometry gates for the 1:2 DC:T cell ratio are shown in Figure 3.5C. While we cannot rule 
out an inability of the DC to phagocytose the virus as a reason for this difference, the FITC-
OVA data suggests that antigen uptake by DCs occurs normally and therefore is likely not a 
factor in the reduced ability of the DC to stimulate CD8+ T cell IFNγ production.  
 
 
 
Obese mice have altered antigen specific CD8 T cells responses during infection  
 The reduced effectiveness of DC from obese mice to stimulate CD8 T cells, 
suggested that DC MHC Class I presentation was impaired and also suggested that obese 
mice may have altered T cell responses.  To address this issue, we analyzed T cells in the 
lung at day 7 p.i. to determine the magnitude of the antigen specific response in influenza 
infected obese mice. Additionally we evaluated MHC Class I expression on the DC during 
infection. Virus-specific CD8+ T cells were identified by DbNP366-PE tetramer binding, a 
peptide derived from the viral nucleoprotein which has been shown to be an epitope 
recognized by a high percentage of CD8+ T cells (236). Though we found no difference in 
DC MHC Class I expression between lean and obese mice (data not shown), we did find 
differences in their antigen specific CD8+ T cell response. Surprisingly, we found the 
frequency of NP366-specific CD8+ T cells was significantly higher in obese mice compared to 
lean (Figure 3.6A). In agreement with previous studies (237), about 14% of CD8+ T cells 
from lean  mice were NP366-specific, whereas in obese mice, 26% of CD8+ T cells were 
influenza-specific.  This increase was also seen when the proportion of antigen-specific 
CD8+ T cells from BALF was determined by IFNγ ELISPOT (Figure 3.6B). In this assay, 
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splenocytes were pulsed with influenza and therefore present a variety of viral peptides. We 
found a 40% increase in the frequency of influenza-specific CD8+ T cells in obese mice.  The 
similarity of the response between the two assays indicates that obese mice have a general 
increase in the percentage of antigen-specific CD8+ T cells.  Additionally, the ELISPOT 
indicates that antiviral responses are functional in the effector CD8+ T cells.  
 
 Despite a higher proportion of antigen-specific CD8+ T cells, obese mice did not have 
more of these cells in their lungs. When the cell population in the lung was enumerated at d 7 
p.i., we found that obese mice had significantly less CD8+ T cells than lean mice and the total 
T cell population was also less in this group  (Figure 3.6C).  A similar trend was seen in the 
BALF, though the differences were not significant (Figure 3.6D).  Given the fewer number 
of CD8+ T cells in obese mice, the total number of CD8+ T cells specific for antigen is 
comparable between the groups (3.6E and F).  
 
 The decrease in the number of CD8+ T cells may be related to a decrease in IL-2 
production since IL-2 supports CD8+ T cell proliferation (238). Indeed we found that at day 3 
and 7 p.i., expression of IL-2 in the LN of obese mice was significantly diminished (Figure 
3.6G). 
 
E. DISCUSSION 
 In this work, we demonstrate that obesity results in impairment in DC recruitment and 
function during influenza infection. Our previous studies showed that influenza infection in 
obese mice resulted in delayed pro-inflammatory responses and inhibited Type I IFN and 
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chemokine expression (224). This suggested that infiltration of cells into the lungs during 
infection may be altered in obese mice. Indeed, we saw a delay in the recruitment of 
monocytes and DC in the lungs of obese mice, with a sustained decrease in DC numbers 
throughout infection.  
  
 Two major groups of DC exist, pDC and cDC and these can be further subdivided 
based on the expression of cell surface makers (239). pDC express B220 and are major 
producers of IFNα/β (240).  We found that the percent of pDC in the DC population of obese 
mice increases during infection and makes up a significantly larger percent of the population 
than in lean mice, but there are still less total pDC in the lungs of obese mice. Therefore a 
reduction in the number of pDC during infection may explain the diminished expression of 
IFNα we previously observed in influenza infected obese mice (224). Given the low number 
of pDC, however, it is also likely that  the low level of IFNα/β expression during influenza 
infection in obese mice is due to impairment in production by respiratory epithelial cells 
(121).   
 
 In contrast, the proportion of the cDC DN subset decreased during infection in obese 
mice. cDC have high expression of CD11c and are very efficient at stimulating T cell 
responses following migration to the LN.  Studies from Carbone et al, have demonstrated that 
cDC with the DN phenotype bring antigen from the lungs to the LN where it can be 
transferred to LN-resident DC or be presented by the DN DC themselves (223, 241, 242). 
The decrease in the number of DN cells in the lungs of obese mice could have been due to 
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these cells already migrating out to the LN with no new DC coming in, whereas lean mice 
maintain a homeostatic level in the lung.  
 
 Indeed, we did observe a lack of recruitment of cDC to the lungs of obese mice. This 
may be due to the reduction in CCL2 (MCP-1) and CCL5 (RANTES) expression we have 
previously reported at d 3p.i. infection in obese mice (224).  Immature DC respond to these 
ligands through interactions with receptors on the cell surface which promotes chemotaxis of 
the immature cell to the inflamed tissue (243). The lack of chemokine induction may also 
explain the reduced recruitment of monocytes to the lung. Additionally, given that obese 
mice have less TNFα expression at day 3 p.i. (224) differentiation of DC from monocyte 
precursors could also be impaired (160) (244). 
 
 It is unclear what effect the lack of increase in lung DC by d 3 p.i. has on the 
trafficking of antigen to the LN. Legge et al, showed that accelerated migration to the LN 
during influenza infection only occurs within the first 24-48 h p.i. (234, 245).  However, new 
DC continue to enter the LN, but whether these cells are lung derived and play a role in T 
cell responses is unknown (245, 246).  When we assessed the migratory function of lung-
derived DC, we found that obesity resulted in comparable antigen trafficking to the LN 24 h 
after intranasal FITC-OVA instillation indicating that accelerated migration following initial 
antigenic insult is intact in obese mice. These results are similar to another study that used 
ob/ob mice and demonstrated normal migratory capacity of Langherans cells out of the 
epidermis in response to TNFα induced migration (247).  Although migration of DC from the 
lung was similar between lean and obese mice, obese mice had an augmented number of 
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FITC- DC in their lymph nodes. This suggests that obese mice may have an increased 
number of DC in their LN at baseline. Indeed, studies from Verwaerde et al. and Macia et al. 
indicate that this increase is due to greater baseline cellularity. Verwaerde et al. demonstrated 
that the number of splenic DC was greater in diet-induced obese mice prior to ovalbumin 
immunization, however this difference was abolished 5 d following antigenic stimulation as 
both groups had increased the number of DC to a comparable level (53).  Similarly, Macia et 
al, found higher numbers of Langerhans cells in the epidermis of ob/ob mice compared to 
lean mice (247). Whether these resident DC affect the type of response that ensues remains to 
be determined.  
 
 The inability of DC from obese mice to properly stimulate T cells may be due to 
altered cytokine production. This was shown in ob/ob mice where the altered cytokine milieu 
resulted in less potent stimulation of allogeneic T cells by bone marrow derived DC, despite 
similar expression of co-stimulatory molecules. (247). In our study, the dampened expression 
of IL-12 in obese mice may mediate the reduction in T cell responses given that IL-12 acts 
directly on CD8+ T cells to augment cytolytic activity and IFNγ production (125, 126). 
Likewise, the overproduction of IL-6 in the AM and monocyte population of obese mice 
could impair DC presentation. Exaggerated IL-6 production can inhibit monocyte 
differentiation into DCs and prevent their maturation (248, 249). Previous reports indicate 
that IL-6 can switch DC progenitor commitment away from a DC toward a phenotype that 
can phagocytose but cannot present antigen  (249). Additionally, IL-6 blocks MHC Class II, 
CD80, and CD86 expression on DC, but does not affect MHC Class I (248).  Therefore the 
impairment in antigen presentation, without a reduction in MHC Class I expression we find 
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in DC from obese mice, could be due to the fact their macrophage are producing more IL-6 
than lean mice.  
  
 In spite of a reduced ability of the DC from obese mice to stimulate CD8+ T cells 
from lean mice, influenza-specific CD8+ T cell responses in vivo remained relatively intact in 
obese mice.  Due to the essentiality of an effective immune response, the immune system has 
evolved to dynamically eradicate infection when components of the response are deficient 
(131, 154, 237, 250). In this study we found that while influenza infected obese mice had less 
CD8+ T cells infiltrating the lung, the frequency that were virus-specific was higher which 
resulted in a total number of antigen-specific cells that was comparable to lean mice.  The 
CD8 response elicited by obese mice suggests that more of the CD8 precursor pool is being 
utilized to clear virus (130). Although this is effective for clearing a primary influenza 
infection, it may result in a compromised memory response (130, 237).  
 
 The decrease in total CD8 T cells in obese mice could be due to reduced trafficking to 
the lungs or to reduced proliferation. IL-2 from CD4+ T cells plays a significant role in CD8+ 
T cell proliferation (238) and its expression inversely correlated with SOCS3 (suppressor of 
cytokine signaing protein 3) expression (251). SOCS proteins are a family of cytokine-
inducible negative feedback inhibtors that target cytokine receptors and cytoplasmic 
signaling adaptor molecules (252).  In diet-induced obesity, SOCS3 upregulation has been 
suggested as a mediator of the impaired STAT3 DNA binding that occurs in T cells from 
these mice (77). Therefore it is possible that the reduction in CD8+ T cell number we 
observed in obese mice was due SOCS3 inhibited proliferation via prevention of IL-2 
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expression. Another possibility is that if antigen is not efficiently presented then it would not 
be surprising to have less T cell activation and proliferation (234).  
 
 In conclusion, we demonstrated that diet-induced obesity results in selective 
impairment of DC functions. Our data indicate that during influenza infection, obesity leads 
to delayed recruitment of mononuclear cells to the infected lung. DC, in particular, are 
noticeably low throughout infection. While migration of antigen-loaded DC to the LN is 
normal in obese mice, the ability of the DC to present antigen to CD8 T cells is impaired. 
This may be due to lack of co-stimulation by the DC. The outcome of these alterations was 
an elevated frequency of virus-specific CD8+ T cell response in obese mice. Further studies 
are needed to elucidate the exact mechanism behind these changes in obese mice and 
determine if these alterations result in defective memory responses.   
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Figure 3.1. Gating strategy to identify cell populations in lungs. CD11b and CD11c 
expression was used to identify alveolar macrophage (R1), dendritic cells (R2), 
monocytes/interstitial macrophage (R3). 
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Table 3.1. Total number of cells in the lung during influenza infection.  
Cell populations from total lung were identified by CD11b and CD11c expression at various 
time points p.i. Data are expressed as mean (SEM) of 3-6 animals per group per time point. 
*Indicates significantly different from lean mice, P ≤ 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cell Type Phenotype Day 0  
Cell # x 105 
(SEM x 105) 
Day 3 
Cell # x 10 5 
(SEM x 105) 
Day 6 
Cell # x 105 
(SEM x 105) 
Total cells Lean Obese 
101 (13.0)  
74.5  (11.6)  
118 (11.9)  
*67.2 (8.6)  
294 (35.0)  
188 (32.8)  
Alveolar Mac Lean Obese 
6.4 (0.69) 
*3.1 (0.96) 
5.9 (0.49) 
*4.4 (0.31)  
13.2 (2.3)  
7.9 (1.6)  
Monocyte/Interstitial 
Macrophage 
Lean 
Obese 
18.8 (3.1)  
17.8 (2.4)  
44.7 (5.2)  
*18.9 (3.0)  
80.8 (14.9)  
59.4 (14.1)  
Dendritic Cell Lean Obese 
15.6 (2.2) 
16.0 (2.4) 
25.8 (1.7) 
*11.6 (1.2) 
90.0 (12.3) 
*55.6 (9.3) 
CD11b-/CD11c- Lean Obese 
62.0 (7.2)  
54.1 (9.7 
41.0 (4.0)  
31.4 (3.6)  
101 (13.6)  
*59.1 (10.2)  
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Figure 3.2.  IL-6+ cells in lung during infection. Single cell suspensions from influenza 
infected lungs were surface stained with anti-CD11b and anti-CD11c following a 4-6 h 
incubation  with Brefaldin A. (A). Total number of IL-6+ cells in lung. (B) The percent IL-6 
production at day 3 p.i. was determined for AM and monocyte populations using gating 
strategy described earlier (see Figure 3.1).  Data are expressed as mean SEM ± of 5-6 
animals per group per time point. *Indicates significantly different from lean mice, P ≤ 0.05. 
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Figure 3.3. Population of DN and pDC in total DC population during influenza virus 
infection. In the lung DC were identified by flow CD11c CD11b expression (A) DN cells 
were identified as CD8-B220- at d 0 and 3 p.i. (B) Gating strategy to identify the proportion 
of DN DC and pDC. Values listed represent the mean percentage in the DC population. The 
percent pDC includes all B220+ cells in the DC gate. (C) Based on the percent of pDC found 
in (B), the total number of pDCs in the lung was calculated.  Data are expressed as mean 
(SEM) of 3-6 animals per group per timepoint. *Indicates significantly different from lean 
mice, P < 0.05. 
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Figure 3.4. Migration of lung DC to LN. DC in the LN were identified by their expression of 
CD11c. (A) The total number of FITC+ DC was identified 24 h after intranasal FITC-OVA  
instillation. (B) Numbers indicate percent of FITC+ cells in the DC population. (C) DN DCs 
were identified by the lack of CD8 and B220 from CD11c+ cell population. The total number 
of FITC+ DN DCs was determined by analyzing the percent of DN DCs that were FITC+ in 
the LN 24 h after FITC-OVA treatment (D). Data in bar graphs are expressed as mean ± 
SEM of 3 experiments with 3-5 animals per group per experiment. *Indicates significantly 
different from lean mice, P ≤ 0.05 
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Figure 3.5. Stimulation of T cells with viral antigen presented by DC. (A) LN mRNA 
expression of IL-12 was quantified by real-time PCR using total RNA extracted from lungs 
of 6-8 mice per group. Values are normalized to GAPDH and are expressed as mean fold 
increase ± SEM over lean controls at d 3 p.i. (B) An antigen presentation assay was 
performed using T cells from influenza infected chow-fed mice at d 7 p.i. mixed with varying 
numbers of  influenza-loaded DCs from uninfected lean and obese mice. The percent of 
CD8+ cells in the CD3+ lymphocyte population that produced IFNγ after 6 hours of 
stimulation was determined by ICS. Data are representative of two separate experiments (n= 
4-5 mice/group). (C) Gating strategy for determining the percent of CD8+ T cells with IFNγ. 
Data are expressed as mean ± SEM, *, significantly different from lean mice, P ≤ 0.05 
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Figure 3.6. Increased frequency of antigen specific CD8+ T cells in obese mice. (A) The 
percent of NP366+ in the CD8+ cell population in the total lung was determined by flow 
cytometry at d 7 p.i. The values presented for lean and obese account for the non-speicfic 
staining shown in the first panel (B) An IFNγ ELISPOT was performed with 104 CD8+ T 
cells obtained from the BALF by negative isolation. Influenza pulsed splenocytes were used 
as APCs, values are presented as mean (SEM). Flow cytometry was used to enumerate total 
CD3 and CD8 in the lung, (C) and BALF (D). The total number of antigen specific CD8+ T 
cells in the lung (E) and BALF (F) was calculated by multiplying the percent of antigen 
specific CD8+ cells determined by flow cytometry and ELISPOT, respectively, by the total 
number of CD8+ T cells in the CD3 population. Data are expressed as mean ± SEM, *, 
significantly different from lean mice, P ≤ 0.05 
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 CHAPTER IV 
CENTRAL LEPTIN RECEPTOR SIGNALING RESCUES DEFECT IN NATURAL 
KILLER CELL CYTOXICITY IN db/db MICE DURING INFLUENZA INFECTION.   
 
 
A.  ABSTRACT 
 The incidence and prevalence of obesity worldwide are increasing at an alarming rate. 
Obesity increases the risk of metabolic disease and has been shown to increase susceptibility 
to infection. Adipokines, such as leptin, have been identified as a direct link between adipose 
tissue and immune responses. We have previously observed dysregulated innate and cell-
mediated immune responses in obese mice during influenza infection, including reduced T 
cell numbers and impaired NK cell cytotoxicity. To investigate the mechanism that underlies 
these phenomena, we analyzed splenocyte signaling and function in obese mice. We 
observed a lack of STAT3 activation in obese mice during infection as well as reduced PHA-
induced splenocyte proliferation. Since leptin signals through STAT3 and effects both T cell 
proliferation and NK cell cytotoxicity, we determined a role for leptin signaling in the 
aberrant immune responses. Using a transgenic mouse model, we show that central leptin 
signaling is sufficient to rescue NK cell function in the db/db mouse that lacks functional 
leptin receptor.  Thus our data suggest that impaired central leptin signaling may mediate 
some of the changes in immune function that occur in obese mice infected with influenza 
virus
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B. INTRODUCTION 
 The incidence and prevalence of obesity worldwide are increasing at an alarming rate. 
Obesity increases the risk of metabolic disease and has been shown to increase susceptibility 
to infection (23-25). While it has been clear for some time that a lack of adipose tissue, such 
as in starvation, leads to immune dysfunction, high obesity rates have generated interest in 
modulation of immune function by excess adipose tissue (6).  In recent years a link between 
adipose tissue and the immune system has been identified, though the exact mechanisms by 
which they communicate are still largely unknown (7, 253-255).  
 
 Various molecules secreted from adipose tissue, collectively known as adipokines, 
have been identified as potential modulators of immune function (3, 96). Leptin and 
adiponectin are two adipokines that are abundantly produced by adipocytes.  Adiponectin 
activates peroxisome proliferators activated receptor-α (PPARα) and AMPK which increase 
glucose uptake and fatty acid oxidation (4). Adiponectin also has anti-inflammatory 
properties and the low levels that occur in obesity and insulin resistance are associated with 
increased levels of C-reactive protein and IL-6 (256, 257). Conversely, leptin circulates in 
proportion to fat mass and acts centrally and peripherally to regulate food intake, 
hematopoiesis, reproduction, glucose homeostasis, and immune responses (65). Thus mice 
that lack leptin, or its receptor, have dysregulation of these functions.  
 
Leptin’s effects are mediated through its interaction with receptors found on almost 
all cell types including neuronal cells (36), NK cells (258), dendritic cells (98), macrophage 
(97), and T cells (6).  Upon binding to its receptor, leptin stimulates a signaling cascade that 
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begins with the phosphorylation of tyrosine (pY) residues on the receptor’s intracellular 
domain by a noncovalently bound Janus kinase (JAK) (259) (66). The phosphorylated 
receptor recruits a tyrosine phosphorylated-signal transducers and activators of transcription 
(STAT pY) to the receptor complex. STAT3, 5, and 6 mediate the transcriptional effects of 
leptin upon entry into the nucleus (82). Negative regulation of leptin signaling occurs through 
the recruitment of suppressor of cytokine signaling 3 (SOCS3), which is recruited to the pY 
on the receptor and prevents JAK2 phosphorylation (88).  Recent evidence suggests that 
obesity leads to upregulation of SOCS3 and causes attenuation of STAT3 DNA binding in  T 
cells (77) and liver (93). Therefore, if leptin signaling in immune cells is inhibited, immune 
responses may be dysregulated.  
 
 The effect of leptin on immune function is generally thought to be pro-inflammatory, 
therefore, it is not surprising that leptin increases during infection (6, 63). Leptin’s role in 
inflammation was demonstrated in models of inflammatory diseases. In experimentally 
induced colitis, mice that lack leptin are protected from the intestinal inflammation and have 
less pro-inflammatory cytokine secretion. However, administration of leptin increases 
cytokine production in these mice to that of controls (100).  Similarly, humans that are 
congenitally deficient in leptin, have reduced numbers of circulating CD4+ T cells and 
impaired T cell proliferation and cytokine release, all of which were reversed by leptin 
administration (260). Moreover, leptin promotes NK cell development and cytotoxicity as 
demonstrated by impaired NK cell function in db/db mice, which lack the leptin receptor 
(102). Whether the correction in these responses is due to direct action of leptin on immune 
cells or indirectly through neuronal signals is unknown.  
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Our lab has previously shown diminished and delayed inflammatory responses, 
impaired NK cell cytotoxicity, as well as reduced T cell proliferation in obese mice infected 
with influenza. In this paper we assess the role of leptin in these changes.  
 
 
C. MATERIALS AND METHODS 
Animals 
  Male weanling C57BL/6J mice were obtained from Jackson Laboratories (Bar 
Harbor, MA). All mice were housed in the University of North Carolina Animal Facility, 
which is fully accredited by the American Association for Accreditation of Laboratory 
Animal Care. Animals were maintained under protocols approved by the Institutional Animal 
Use and Care Committee.  Mice were randomized to receive either a low fat/no sucrose diet 
(LF) or a high fat/high sucrose (HF/HS) diet for 20 weeks. Mice were housed four per cage 
with free access to food and water. 
 
Diets 
 The diets were obtained from Research Diets, Inc. (New Brunswick, NJ). The LF diet 
(D12328) consisted of 16.4% protein, 73.1% carbohydrate (83% starch, 17% maltodextrin), 
10.5% fat (38% soybean, 62% coconut oil).  The HF/HS diet (D12331) consisted of 16.4% 
protein, 25.5% carbohydrate (51% sucrose, 49% maltodextrin), 58% fat (93% coconut oil, 
7% soybean oil). 
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Virus and Infection 
 Mouse adapted Influenza A/Puerto Rico/8/34 (A/PR8) (American Type Culture 
Collection) was propagated in the allantoic fluid of fertilized chicken eggs and the viral titer 
was determined by hemagglutination assay (48). After 20 weeks on the diets, mice were 
anesthetized with an intramuscular injection of a ketamine (0.022mg)/xylazine (0.0156mg) 
solution and infected intranasally with 0.05 mL of 50 plaque forming units (pfu) of influenza 
A/PR8 virus diluted in PBS.  
 
Cell proliferation 
  Splenocytes were isolated from lean and obese mice (n=3/group) and pooled. 2.5 x 
106 cells were plated in each well of a 96 well plate. Cells were stimulated for 48 h with 2.5 
µg/mL phytahemagglutinin (PHA) (Sigma). During the last 4 hours of stimulation, cells were 
pulsed with 2 µCi [3H] thymidine and proliferation was assessed by thymidine incorporation, 
measured by liquid scintillation counting. 
 
Western blot 
 
 Protein extracts were prepared from splenocytes at d 0 and 7 p.i. using Pessin’s Lysis 
Buffer. Protein extracts were separated by 10% SDS-PAGE, electroblotted to Immobilon-P 
membranes (Millipore, Burlington, MA) and probed with anti-STAT3 pY and anti-β-actin 
(Abcam, Cambridge, MA). The antigen-antibody complexes on immunoblots were treated 
with horseradish peroxidase–conjugated secondary antibodies (Santa Cruz Biotechnology) 
and visualized using autoradiography or the Gene Gnome imaging system (Syngene, 
Frederick, MD). 
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Serum glucose, corticosterone, and adipokines 
 Blood was collected from mice, allowed to clot at room temperature for 20 min, 
centrifuged at 2500 rpm for 20 min, and serum was collected and stored at -20 until analysis. 
Full-length adiponectin and leptin were analyzed by ELISA according to the manufacturer’s 
instructions (R & D Systems). Blood glucose levels were measured with a Freestyle blood 
glucose monitor (Abbott Laboratories). Corticosterone was measured by RIA (MP 
Biomedical) from blood collected at 0800 by retrooribital bleed on anesthetized mice prior to 
infection. Following infection, mice were sacrificed and blood was collected by cardiac 
puncture. 
 
Transgenic mice (Nse-Rb db/db) 
 Transgenic expression of the long form of leptin receptor (Ob-Rb) under the control 
of the neuron-specific enolase (Nse) promoter was shown to partially correct the abberent 
phenotype of db/db mice (36). Expression of the functional receptor was limited to the 
hypothalamus, the cortex, and the cerebellum, with low levels seen in the adrenals, white 
adipose tissue, and the testis. The mice in the published report were backcrossed three times 
to db/+ C57BL/6J background which were then mated to generate Nse-Rb db/db mice. In our 
study the Nse-Rb db/db were the FVB strain.  Like C57BL/6 db/db mice, FVB db/db mice 
develop severe obesity, hyperglycemia, hyperinsulinemia, and hyperleptinemia.  
 
 Tables 4.1 and 4.2 (36) document the phenotype of the heterozygous transgenic mice. 
In addition to partial normalization of body weight, glucose, insulin, and leptin, these mice 
have near normal thermogenesis and reproduction, though female mice were not able to 
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produce a litter. In male Nse-Rb db/db mice POMC, AgRP, and NPY are relatively normal, 
while MCH was not affected.  
 
Analysis of genomic DNA 
 Transgenic mice were identified using PCR analysis of DNA isolated from tail snips. 
Tissue was digested in    overnight at 65oC and DNA was isolated using the phenol 
chloroform method. Amplification of the trangene was performed using the following 
primers: Nse forward 5’-CCACCGGCTGAGTCTGCAGT-3’ and rGHint reverse 5’-
TTGGCGCGCCGAGAGTCTAGAAAGAGAGACA-3’. If the transgene was present a 242 
bp product was produced, whereas there was no product if the trangene was absent (36). The 
db/db genotype was determined by PCR amplification followed by RsaI restriction digest. 
Primers to the leptin receptor were as follows: db forward 5’-
AGAACGGACACTCTTTGAAGTCTC-3’ and reverse 5’-
CATTCAAACCATAGTTTAGGTTTGTGT -3’. 50µl of amplified product was digested 1U 
of RsaI restriction enzyme at 37oC for 3 h. Digests were run on a 3% agarose gel made with 
1% low melting agarose. If a 108 and 27 bp product was present the genotype was 
considered db/db and if a 135 bp fragment was present the genotype was wild type.  
 
 
Enumeration of NK cell populations in the lung and spleen  
 At d 3 p.i. spleens were removed, processed into single cell suspensions by 
mechanical agitation of a Stomacher (Seward, UK), and strained through a 40µm nylon filter.  
Cells were stained with fluorescein (FITC)-labeled anti-DX5 and Phycoerythrin (PE)-labeled 
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anti-CD3 (BD Pharmingen, San Diego, CA) and analyzed by FACSCaliber.  The lymphocyte 
population was gated and NK cells were identified as CD3-DX5+ within that gate. 
 
Determination of natural killer cell cytotoxicity 
 Spleen cells were analyzed in a standard NK cell cytotoxicity assay (190), using 51Cr-
labeled YAC-1 tumor cells (ATCC) as targets. Briefly, serial dilutions of 0.1 mL lung or 
spleen effector cells, starting at 1 x 107 cells/mL, were plated with 1 x 104 cells 51Cr labeled 
YAC-1 target cells in a 96-well V-bottom microplate. The resulting effector to target (E:T) 
ratios were 100:1, 50:1, and 25:1. All samples were prepared in triplicate. To determine 
maximum lysis, 0.1mL of 10% sodiumdodecylsulfate was added to labeled YAC-1 cells. To 
determine spontaneous release 0.1 mL of the culture media was added to radioactive YAC-1 
cells. Release of 51Cr content was analyzed using a gamma counter (Cobra II, Hewlett 
Packard) and percent specific lysis was calculated by the following equation:  
 
  % specific lysis =   cpm (sample) – cpm (spontaneous release)     x 100 
    cpm (maximum release) – cpm (spontaneous release) 
 
 
Statistical Analysis 
 Statistical analyses were performed using JMP Statistical Software (SAS Insititute).  
All results are expressed as mean ± SEM. Statistical significance was calculated using 
Tukey-Kramer HSD or Wilcoxon signed ranks test, α = 0.05 and P < 0.05, respectively. 
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D. RESULTS 
 
 
Adiponectin and leptin are unchanged during infection in obese mice 
 As, expected a high fat diet induced elevated serum leptin levels (Figure 4.1A). We 
found that after 1 week on a high fat diet, mice fed the HF diet have elevated leptin levels, 
which continue to increase as the time on the diet progresses. By day 0 post infection (week 
20 of the diet), obese mice have serum leptin levels that are 7 times higher than lean mice. 
Following influenza infection, lean mice have a transient increase in leptin, whereas serum 
leptin in obese mice remains elevated and does not change, possibly because leptin levels are 
already maximized (Figure 4.1B). These data indicate leptin levels in obese mice are 
unresponsive to infection, and suggest that leptin’s role in the stimulation of immune 
responses may be altered in obese mice.  
 Adiponectin was significantly reduced at baseline in obese mice, in agreement with 
previous studies (261). During infection, adiponectin decreased in lean mice, but remained 
low and unchanged in obese mice (Figure 4.1C).  
 
 Corticosterone levels were significantly elevated in obese mice prior to infection 
(Figure 4.1D). Interestingly, during infection corticosterone levels increased in lean mice, 
whereas obese mice have a temporal decrease in circulating levels.  
 
Less STAT3 phosphorylation in splenocytes of obese mice during infection. 
 The effects of leptin are mediated through STAT3 DNA binding (65). For STAT3 to 
dimerize and enter the nucleus it must be phosphorylated by JAK2. Given that leptin was 
elevated prior to infection in obese mice, we wanted to determine if STAT3 was 
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differentially activated prior to and during influenza infection. Analysis of splenocytes prior 
to infection revealed that both lean and obese mice had low constitutive STAT3 
phosphorylation (Figure 4.2). During infection though, STAT3 phosphorylation increased in 
lean mice, whereas levels remained unchanged in obese mice.  Given that the spleen is a 
secondary lymphoid organ, high numbers of T cells, macrophage, NK cells, and dendritic 
cells can be found there during infection.  Therefore these data suggests that responding 
immune cells from obese mice are resistant to leptin signaling.  
 
Reduced proliferation and IFNγ production in splenocytes from obese mice.  
 Leptin signaling through STAT3 promotes cell proliferation and the production of 
IFNγ by CD4 T cells (87, 162, 262). The lack of STAT3 activation during infection in obese 
mice suggested these responses may be impaired. We stimulated proliferation in splenocytes 
from uninfected lean and obese mice with PHA, a lectin that mimics antigen-receptor 
signaling and induces IL-2 and IL-2R in T cells (263). As shown in Figure 3A, we found that 
splenocytes from obese mice had reduced basal proliferation. PHA induced a strong 
proliferative response in both groups, but proliferation remained almost 40% lower in obese 
mice (Figure 4.3A). Interestingly, the proliferative response was augmented in obese mice, as 
indicated by a stimulation index (SI) of 9.7 versus 6.5 in lean (Figure 4.3B).  
 
 IFNγ is produced by CD4 T cells in response to antigen presented within a specific 
cytokine milieu. Signaling by leptin has been shown to potentiate IFNγ production by these 
cells. We found that IFNγ production by PHA-stimulated splenocytes from obese mice was 
reduced 7-fold compared to lean mice (Figure 4.3C). These data indicate that T cells in obese 
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mice are capable of proliferating upon activation, but the Th1 polarizing effects of leptin may 
be absent.  
 
Direct action of leptin is not necessary for normal NK cell function 
 The lack of STAT3 activation and minimal IFNγ production in splenocytes of obese 
mice, suggested that inhibition of leptin signaling may mediate some of the immune 
dysregulation that occurs during influenza infection in obese mice. We have previously 
shown that obese mice have a 50% reduction in lung and splenic NK cell cytotoxicity (see 
Chapter 2). Leptin is a potent activator of NK cell cytotoxicity, mediating its effects, at least 
in human NK cells lines, through STAT3 activation of IL-2 and perforin (258).  To explore 
the possibility that direct inhibition of leptin signaling in NK cells resulted in their poor 
activation in obese mice, we used a transgenic mouse model that expresses function leptin 
receptor exclusively in the brain. Thus, it provides an excellent model for evaluating the 
effect of leptin on periphery cells without the complicating metabolic abnormalities.  
 
 As shown in Table 4.3, prior to infection, the body weight of mice expressing the 
transgene was significantly lower than db/db, but still higher than Nse-Rb db/db (WT) 
controls. At d 3 p.i. db/db mice were the only group that did not lose weight with infection. 
This lends support to the idea that leptin is involved in inflammatory-mediated anorexia (6, 
201). Additionally, non-fasted blood glucose levels were significantly higher in db/db mice 
compared to both Nse-Rb db/db and WT mice (Table 4.3). During infection though, all 
groups had elevated blood glucose levels which is a normal physiologic occurrence during 
stress (264).   
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 Splenocyte cellularity was similar between the groups, but the frequency of NK cells 
was 10% less in db/db mice and Nse-Rb db/db than WT (Table 4.3).  Previous reports have 
shown that while total cellularity is similar in WT and db/db mice, the percent of NK cells in 
the spleen and blood are lower (68). The affect of the transgene on NK cell cytotoxicity was 
striking, however. As shown in Figure 4.4A, the presence of the Ob-Rb transgene in the brain 
fully corrected the NK cell impairment. At a 100:1 ratio of E:T cells, both the Nse-Rb db/db 
and WT mice had approximately 60% splenic NK cell cytoxicity at d 3 p.i., whereas db/db 
had half that. These data indicate that for full NK cell function, leptin receptor signaling is 
not necessary.  
 
 
E. DISCUSSION 
 In this paper we have documented a potential role for obesity-induced inhibition of 
STAT3 signaling in dysregulated immune responses during influenza infection. We found 
that splenocytes from obese mice have no change in STAT3 signaling during influenza 
infection. This was related to a negligible change in circulating leptin levels, whereas lean 
mice displayed elevated STAT3 pY during infection with concomitant increases in leptin. 
Chronically high circulating leptin has been shown to downregulate its own signaling 
pathway, both by an increase in SOCS3 and downregulation of Ob-Rb (88, 91, 93). 
Therefore this lack of induction during infection in obese mice is likely due to foregoing 
inhibition of the STAT3 signaling caused by high leptin. The comparable levels of STAT3pY 
at baseline in lean and obese mice indicate this is the case, since obese mice have higher 
circulating leptin, but no elevation in STAT3 pY.  
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 It was somewhat surprising that adiponectin decreased during infection in lean mice, 
given that it increases anti-inflammatory molecules like IL-10. However, it also induces 
apoptosis and suppression of scavenger receptors on macrophage, so lower levels during 
infection may be beneficial (265).  
 
 A lack of STAT3 can have numerous effects on immune responses, given it mediates 
the transcriptional effects of leptin, IL-6, IL-10, and IL-27 (266, 267). In T cells a lack of 
STAT3 leads to impairment of IL-6-induced and CD3/IL-2-mediated proliferation by 
preventing apoptosis and inducing IL-2R, respectively (267). The reduced proliferation we 
found in PHA stimulated splenocytes from obese mice may be due to lack of IL-6 signaling 
as the induction of T cell proliferation in response to PHA has been shown to require IL-6 
produced by monocytes (268). Additionally, STAT3 is a part of the IL-27 signaling pathway 
which initiates Th1 responses in naïve CD4 cells, but suppresses inflammatory responses in 
activated CD4 T cells (266). Therefore, in splenocyte of obese mice that do not upregulate 
STAT3 signaling, the lack of IFNγ production could be due to hampered IL-27 induced Th1 
polarization. It should be noted, however, that we have previously reported impaired IL-12 
expression in LN from obese mice.  IL-12 is a potent inducer of Th1 responses and is 
primarily produced by macrophage and DC. Thus, it is possible that the lack of IFNγ 
production in obese mice, is due to impaired IL-12 production by mononuclear cells.  
 
 In this study, we also tested the hypothesis that inhibiting direct leptin signaling on 
cells of the immune response leads to impaired function. We have previously observed 
significant impairment in NK cell cytoxicity in obese mice infected with influenza. Given the 
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fact that leptin induces and augments NK cell cytoxicity (258), we wanted to know if the 
effects we see during obesity could be explained by a lack of leptin signaling in NK cells. To 
do this, we used a mouse model in which expression of a functional leptin receptor is 
restricted to the specific regions of the brain, and therefore leptin signaling in NK cells is 
absent. This model is preferred over the db/db model in which a functional Ob-Rb is 
completely absent. In addition to the severe metabolic changes that occur in db/db mice, 
these mice also have impaired hematopoiesis, thymic atrophy (269), reduced B and T cells, 
and less colony forming potential in lymphoid and myeloid lineage stem cells (270). This 
indicates that these mice are predisposed to immune dysfunction, thus elucidating the direct 
role of leptin on immune cells during infection would be difficult in these mice.   
 
 Nse-Rb expression in db/db mice normalizes metabolic and neuropeptide defects 
relative to db/db mice (36). These mice still weigh more than WT mice due to greater 
adiposity, but they are normoglycemic and have near-normal levels of POMC and 
AgRP/NPY. Though various neuronal factors affect obesity and hyperglycemia (36), 
normalization of these neuropeptides suggests that these are the mediators of some of leptin’s 
peripheral effects.  
 
 NK cell activation, accumulation, and cytoxicity involve various cytokines and 
signaling pathways. Their killing ability relies on IFNα/β signaling through STAT1, which 
also induces IL-15 a cytokine needed for their accumulation and survival (127). In studies of 
NK cell cytoxicity in db/db mice, the addition of IL-15 or PolyI:C (a ligand for TLR3) to NK 
cells induced their killing ability to levels similar to NK cells from WT mice but the 
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augmented effect of leptin addition on NK killing did not occur in the db/db mice (68).  
These experiments suggest leptin acts directly on its receptor to augment NK cell 
cytotoxicity, as any indirect upregulation of TLR3 or IL-15 by leptin would be expected to 
lead to further enhancement of cytotoxicity in db/db mice.  Therefore it is surprising to find 
that Nse-Rb db/db mice have NK cell cytotoxicity that is similar to WT mice despite the lack 
of Ob-Rb signaling.  
 
 To this point, recent research suggests that the milieu of the db/db animal may play 
more of a role in immune function than direct leptin receptor signaling. When bone marrow 
cells from db/db mice were transplanted into WT mice, thymic repopulation and antigen 
stimulated proliferation was similar to control transplants. Moreover, when bone marrow 
cells from the WT mice were transplanted into db/db hosts, thymic atrophy and impaired 
repopulation of the LN occurred (269). Similarly, Unger et al, demonstrated that 
transplantation of adipose tissue depots from WT rats into fa/fa rats, followed by adenovirus-
induced overexpression of leptin, induced no fat depleting effects, whereas WT to WT 
transfers did (271). They proposed a lack of leptin-stimulated catecholamine production or a 
blockade of leptin binding as mechanisms for this effect.  Indeed, treatment with β-
adrenergic antagonists have been shown to mimic the thymic atrophy in db/db mice, and 
administration of norepinephrine (NE) to ob/ob mice reverses the loss of natural killer T cells 
(272). Therefore, the rescue of NK cell cytoxicity that occurs in Nse-Rb db/db mice, may be 
due to normalization of central nervous system signals.  
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 This idea in obesity is exemplified by the fact that obesity is associated with higher 
circulating levels of NE (17, 273). This indicates that obesity upregulates the sympathetic 
nervous system (SNS) which can impair immune cell function (274). Evidence for this in NK 
cells was shown by Gan et al, (2002). This group demonstrated that pre-incubation of 
lymphocytes with NE reduced NK cell killing ability, indicating that NE inhibits the 
programming of the NK cell for cytotoxicity.  
 
 Alernatively, the impaired NK cell function in obese (224) and db/db mice may be 
due to high circulating corticosterone levels. We observed elevated corticosterone prior to 
infection in obese mice, a phenotype that is also characteristic of db/db mice (275). 
Glucocorticoids, in addition to opioids, play a significant role in the suppression of NK cell 
recruitment and cytotoxicty and low leptin is associated with increases in corticosterone (8, 
276). Whether blocking glucocorticoid action would rescue the defect in NK cell cytotoxicity 
in db/db or obese mice, independent of central leptin signaling, is unknown, but would help 
elucidate the mechanism by which central leptin signaling mediates its effects.  
 
 Overall, this paper demonstrates that obesity interferes with normal JAK/STAT 
signaling pathways in splenocyte during influenza infection, and inhibits their proliferative 
capacity and Th1 cytokine production. Though all of these altered responses can be attributed 
to reduced leptin signaling by the splenocytes themselves, we did not find evidence that 
direct leptin signaling is necessary for normal NK cell responses. In fact, the influence of 
leptin on immune function, at least in terms of the NK cell, can be attributed to its central 
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effects.  Importantly, these results provide evidence that central leptin resistance mediates 
some of the obesity-induced immune dysfunction.   
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Table 4.1. Phenotype of Nse-Rb db/db transgenic mice (36) 
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Table 4.2. Serum glucose, insulin, and leptin in Nse-Rb db/db mice (36) 
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Figure 4.1. Leptin levels are chronically elevated in obese mice and do not change with 
infection. Serum leptin (A) was measured every other week during high fat feeding and 
during infection; d 0 corresponds to week 20 of the diet. Serum adiponectin (B) and 
corticosterone (C) were measured during infection by ELISA and RIA, respectively. Values 
are expressed as mean ± SEM (n=6-8). *, P < 0.05 vs. lean, groups not sharing a letter are 
significantly different, P < 0.05. 
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Figure 4.2. STAT3 activation is attenuated in obese mice during influenza infection. Protein 
extracts were prepared from splenocytes at d 0 and 7 p.i. and probed with anti-STAT3 pY 
and β-actin. Values on graphs represent the density of the band and data are expressed as 
mean ± SEM (n = 10/group).  
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Figure 4.3. Obese mice have reduced proliferation and IFNγ production in response to PHA. 
Splenocytes were isolated from lean and obese mice (n=3/group) and pooled. Cells were 
stimulated for 48 h with 2.5 µg/mL PHA and pulsed with  2 µCi [3H] thymidine during the 
final 4 h. Values *, P < 0.05 vs. lean.   
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Table 4.3. Effects of influenza infection on db/db, Nse-Rb db/db, and Nse-Rb +/+ mice. 
Blood was collected from fed mice to determine glucose levels. Percent of NK cells in the 
splenocyte population were determine by flow cytometry. Values are expressed as mean  
(SEM) (n=3/genotype). 
 
 Body Wt (g) 
(SEM) 
Blood glucose 
(mg/dL) 
% NK cell 
(SEM) 
Genotype d 0  d3 d0  d3 d3 
db/db 67 (2.5) 68 (3.2) 245 (31.5) 410 (92.7) 30.6 (3.6) 
Nse-Rb db/db 49 (2.8)a,b 47 (2.3)a,b 135 (10.3)b 250 (32) 31.3 (3.7) 
Nse-Rb +/+ (WT) 28 (0.67)b 25 (1.2)b 135 (7.9)b 200 (30.6) 40.8 (0.96) 
a
 P < 0.05 from WT 
b
 P < 0.05 from db/db 
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Figure 4.4. Central leptin signaling corrects impaired NK cytotoxicity in db/db mice infected 
with influenza virus. At day 3 p.i. isolated spleen cells were analyzed in a standard NK cell 
cytotoxicity assay, using 51Cr-labeled YAC-1 tumor cells as targets. The resulting effector to 
target (E:T) ratios were 100:1, 50:1, and 25:1. Data are shown as mean ± SEM (n=3).  
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 CHAPTER V 
SYNTHESIS 
 
 
A.  OVERVIEW OF RESEARCH FINDINGS 
 The incidence of obesity worldwide has reached epidemic proportions. This has had a 
significant economic and social impact due to the increase in co-morbidities associated with 
obesity. Obesity leads to changes in immune parameters under basal conditions which, 
suggests that obesity may result in impaired immune responses during an infection.  
 
 Influenza virus infection is a leading cause of morbidity and mortality, and proper 
immune regulation is necessary for clearance of virus with minimal damage to the host. 
Given the impairment in immune function observed in obesity, it is plausible that obesity 
leads to dysregulated immune responses during influenza infection, resulting in deleterious 
effects on the host. In this work, we characterized both the innate and cell-mediated immune 
responses to influenza infection in obese mice. Furthermore, we examined the role of leptin 
signaling on immune cell function. This section summarizes our research and provides a 
synthesis our findings.  
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B. Increased Mortality and Altered Immune Function in Diet Induced Obese Mice 
Infected with Influenza Virus  
 
 The initial foray into the study of obesity and the immune response to influenza 
infection, was prompted by previous work that demonstrated obese individuals were less 
responsive to Hepatitis B vaccine (220). Additional work from our laboratory indicated that 
the antibody response to influenza vaccine in obese humans was similarly diminished. This 
suggested obesity leads to impaired immune responses to influenza virus antigen. 
 
 To test this, we used the diet-induced obesity mouse model since it closely models 
human obesity in terms of metabolic, hormonal, and adipose tissue changes (217).  Following 
infection with influenza virus, 42% of the obese mice died, despite the fact they were 
infected with a dose of virus that does not lead to excessive mortality, as only 5% of the lean 
mice died. Since infection with influenza stimulates immune cell infiltration into the lung, 
which can result in mortality, this high mortality suggested that immune responses were 
aberrant in obese mice.  
 
 We began by analyzing constituents of the innate immune response, since these 
initiate the inflammatory response and establish the cell-mediated response. We found that 
obese mice had minimal induction in antiviral cytokine responses, as well as a delay in pro-
inflammatory cytokine expression. Furthermore, their NK cell cytotoxicity was reduced. In 
this study we also found that the induction of chemokines was delayed in obese mice which 
indicated that recruitment of mononuclear cells to the infected lung may not be occurring.  
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 Despite the impaired response, obese mice were able to control their viral titer, 
indicating that an excessive amount of virus was not the cause of death. It has been 
previously demonstrated, by our lab and others, that viral titers do not directly correlate with 
the outcome of influenza infection in terms of viral clearance, lung pathology, and death 
(187, 277). This suggests the immune responses determine the outcome of an influenza 
infection. Although, we did not observe a significant difference in lung pathology between 
the dietary groups, the6 obese mice tended to have greater pathology at d 6 p.i. Whether the 
lung pathology continued to escalate in these mice is unknown, however, the peak in pro-
inflammatory cytokine induction at d 6 p.i. suggests that it does. 
  
 Both obesity and infection are associated with an increase in circulating leptin. We 
found that obese mice have chronically high circulating levels of leptin which did not 
increase further with infection. Leptin activates cells of the immune response and its pro-
inflammatory role during infection is thought to be mediated by its central and peripheral 
actions (8, 77, 94).  The lack of increase in leptin during infection suggested that immune 
cells from obese mice may not be fully activated.  
 
 These data demonstrated, for the first time, that obesity impaired immune responses 
that are central to the innate immune response to influenza virus infection. They also 
indicated that impaired leptin signaling may mediate some of these alterations. Furthermore, 
because of the critical role of the innate immune response in activating the cell mediated 
response, these data suggested that obesity also caused dysregulation of cell mediated 
immune responses during influenza infection.  
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C. Selective impairment in dendritic cell function and altered antigen-specific CD8+ T 
cell responses in diet-induced obese mice infected with influenza virus 
  
 In the previous study we found that obesity led to diminished and delayed cytokine 
production during influenza infection. To determine if this was the result of impaired cellular 
recruitment or defective cell function, we analyzed the lung cell population during influenza 
infection. We found that obese mice have delayed recruitment of mononuclear cells into their 
lungs. This impaired recruitment may be due to a lack of induction of chemotactic stimuli 
from the infected macrophage and epithelial cells. Indeed, we saw significantly lower 
expression of chemokines in the lungs of obese mice at d 3 p.i.  Therefore, it appears that 
obese mice have slower infiltration of immune cells to the infected lung, which may explain, 
in part, their delay in pro-inflammatory cytokine expression.  
 
 To determine if the altered cytokine levels in obese mice was also due to an 
impairment in the cells capacity to produce cytokines, we analyzed the ability of lung cells to 
produce IL-6 during influenza infection.  We found that despite a lower number of 
mononuclear cells at d 3 p.i. in obese mice, these cells were capable of producing IL-6 and, 
in fact, produced more IL-6 than mononuclear cells from lean mice.  
  
 The overproduction of IL-6 by the monocyte population may be due to minimal 
STAT3 activation (Chapter 4). STAT3 mediates IL-10 suppression of IL-6. So although IL-6 
also signals through STAT3, the role of this signaling molecule is predominantly anti-
inflammatory (86). This indicates that a defect in the activation of this pathway could result 
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in “hyperproduction” of inflammatory cytokines, such as IL-6. A defect in STAT3 signaling 
could also explain the heightened induction of pro-inflammatory cytokines that occurs at d 6 
p.i. in obese mice (Chapter 2). So although mononuclear cells from obese mice are slower to 
enter the lung during influenza infection, once they are there they may be in an augmented 
pro-inflammatory state.  
 
 Analysis of lung cellularity also revealed that obese mice had a continual reduction in 
the number of DC that entered the lung during infection. Since DC play a critical role in 
establishing the cell-mediated immune response we explored their functional capacity and 
the subsequent T cell response. As shown in Chapter 3, we found that DC from obese mice 
had limited ability to stimulate CD8+ T cells. However, their capacity to take antigen up and 
migrate to the LN was normal. Therefore obesity affects specific components of DC 
function. The possibility arises, though, that DC were capable of presenting antigen, but were 
not able to appropriately stimulate T cells due to impaired IL-12 production. Evidence for 
this comes from the fact that we found similar MHC Class I expression between lean and 
obese mice, but IL-12 was significantly reduced in obese mice. However, the inability to 
induce T cell responses could be due to both a defect in antigen presentation as well impaired 
IL-12 expression. The overproduction of IL-6 by monocytes/macrophages suggests this may 
be what is occurring. IL-6 impairs both DC differentiation and maturation resulting in a 
lower number of DC, as well as DC that are ineffective at stimulating T cells.  Therefore it is 
possible that defective STAT3 signaling leads to exaggerated production of IL-6 in 
macrophage, which then interferes with normal DC maturation and function.   
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 Since the major role of the DC is to stimulate T cell responses, and we found that 
DCs from obese mice were limited in their capacity to do this ex vivo, we analyzed the 
population of T cells in the lungs of obese mice during influenza infection.  Using two 
different methods we found that obese mice had a higher frequency, but similar number of 
virus-specific CD8+ T cells and less total CD3+ and CD3+CD8+ T cells. Additionally, upon 
antigen encounter they were able to produce IFNγ. These data indicate that: 1. T cell 
proliferation is reduced or apoptosis is increased in obese mice  2. CD8+ precursor T cells 
are fully utilized and thus depleted 3. T cell antiviral function is preserved.  
 
 The inability of T cells to proliferate could be due to alterations in the cytokine milieu 
during influenza infection in obese mice, and/or to a lack of STAT3 signaling.  As described 
in Chapter 4, we found that STAT3 signaling in splenocytes at d 7 p.i. was impaired. STAT3 
mediates IL-6 induced T cell entry into the G1 phase of the cell cycle resulting in 
proliferation and IL-2 production (278). Thus, the diminished IL-2 expression we observed in 
the LN during at times of peak T cell proliferation indicates that T cell responses are 
impaired and this may be due to altered IL-6 signaling. This is further suggested by the fact 
that splenocyte proliferation was lower in obese mice following PHA-stimulation (Chapter 
4). PHA-stimulated T cell proliferation has been shown to be IL-6 dependent (268).  Since 
IL-6 mediates it effects via STAT3, these data therefore suggest, that the lower number of T 
cells in the lungs of obese mice is due to reduced STAT3 mediated cell proliferation. 
Notably, leptin also signals through STAT3 to increase T cell proliferation. This suggests 
that limited STAT3 signaling may also blunt any proliferative signal induced by leptin. There 
is, however, there is an alternative explanation for the lower T cells numbers that occur in 
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obese mice. It may be that T cells in obese mice are more prone to apoptosis. Evidence for 
this, comes from the fact that both leptin and IL-6 suppress apoptosis through STAT3 
activation. Thus, overall it appears that the reduced number of T cells in obese mice is likely 
due to impaired STAT3 signaling.  
 
 Additionally, the higher frequency of antigen specific cells within the stunted T cell 
population in obese mice, suggested that the pool of precursor CD8+ cells were fully utilized 
to eradicate virus. During a normal CD8+ T cell response, there is a proportion of the antigen 
specific population that does not gain effector function, i.e. the precursor CD8+ T cell. These 
cells appear to be important in establishing the memory response to influenza. However, 
when the number of T cells is limiting, the proportion of these cells that are used as effectors 
increases (130). So while the higher frequency of antigen-specific effector CD8+ T cells was 
probably beneficial to the obese mice, in that it allowed them to clear antigen, it may have 
deleterious effects on subsequent immune responses.  
 
 Finally, the ELISPOT data revealed that T cells from obese mice were capable of 
eliciting antiviral responses.  This was indicated by the production of IFNγ by T cells 
following antigenic stimulation. This is in contrast to the limited production of IFNγ from 
PHA-stimulated splenocytes from obese mice (Chapter 4). This difference may be due to the 
fact that the ELISPOT is performed with antigen presenting cells that are derived from lean 
mice. Therefore, if a lack of DC derived cytokines mediates the impairment in IFNγ 
production in obese mice, any defect in IFNγ production by T cells will not observed in the 
ELISPOT assay.  
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 These data demonstrated that cell-mediated responses in obese mice were affected by 
obesity. Many of the alterations, however, may be caused by impaired innate immune 
responses. From our data, it is reasonable to hypothesize that impaired STAT3 signaling 
plays a significant role in the innate and cell-mediated immune dysfunction we observed in 
obese mice.  
 
D.  Central leptin receptor signaling rescues defect in natural killer cell cytoxicity in 
db/db mice during influenza infection.   
 At this point in our investigation, we did not know if STAT3 activation was altered. 
What we did know was that pro-inflammatory cytokine expression was delayed, NK cell 
cytotoxicity was impaired, and the number of T cells was less in obese mice.  All of these 
changes were consistent with the idea that obesity leads to impaired leptin signaling in 
immune cells, since leptin has been shown to augment pro-inflammatory cytokine 
production, enhance NK cell mediated killing, and stimulate T cell proliferation and Th1 
polarization. Additionally, there was evidence that leptin-induced STAT3 signaling was 
inhibited in T cells from DIO mice (77).  Therefore, we hypothesized that obesity caused a 
reduction in leptin signaling in immune cells, thereby preventing full activation of normal 
immune responses.  
 
 To determine if leptin receptor signaling in immune cells was necessary for complete 
activation of immune responses, we analyzed NK cell cytoxicity. This marker of immune 
function was chosen because we had previously observed a 50% reduction in NK cell 
cytotoxicity in obese mice (Chapter 2) and because leptin receptor has been shown to be 
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necessary for leptin-induced augmentation of NK cell cytotoxicity.  We used a transgenic 
mouse model in which expression of a functional leptin receptor is restricted to the brain, and 
therefore leptin signaling in NK cells is absent. When we analyzed the ability of NK cells 
from these mice to kill target cells, we found that NK cell killing in the transgenic mice was 
restored to the level of WT mice. However, the db/db mice had significantly impaired NK 
cell cytotoxicity. These data indicate that direct leptin signaling on NK cells is not required 
for complete activation of NK cell cytotoxicity.  
 
 Evidence for direct leptin-mediated augmentation of pro-inflammatory effects comes 
from in vitro and ex vivo studies where exogenous leptin is added to cells and responses are 
measured. Because immune cells have receptors for leptin, it is not surprising that leptin 
transduces a signal and activates target responses in these models. Our data suggest, though, 
that this is not necessarily how leptin’s effects are mediated in vivo. To this point, both leptin 
and obesity can alter neuromodulators, such as catecholamines, glucocorticoids, and 
neuropeptides, all of which have significant effects on immune responses (279).  Therefore, 
in vivo, leptin’s effects on immune function may be mediated by these factors. 
 
 It is important to note, however, that we only tested NK cell function. Macrophage, 
DC, and T cells all possess leptin receptors and have been shown to be responsive to leptin. 
Furthermore, our data indicate a defect in STAT3 signaling during infection in obese mice, 
therefore any cytokine whose function is mediated by STAT3, namely IL-6, IL-10, leptin, 
and IL-27, may play a role in the dysregulated immune responses we observe in obese mice.   
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` Finally, the fact that neurospecific leptin signaling rescued NK cell function has 
important implications. There is increasing evidence for the idea that obesity leads to 
defective leptin signaling in the brain (280). Thus, if central leptin signaling is critical for 
maintaining normal immune function, it is quite possible that the immune defects that occur 
in obese humans are, in large part, due to impaired leptin signaling in the brain.   
 
E. FUTURE STUDIES 
 
1. Catecholamine/neuropeptide mediated changes in immune function 
 Obese mice and humans have an upregulated sympathetic nervous system which can 
modulate immune function.  Given the fact that leptin alters neurohormone and neuropeptide 
levels, the effects we see on immune function in obese mice may be mediated through these 
molecules. The studies done in Chapter 4 clearly demonstrate that leptin is involved in 
neuroendocrine regulation of immune function. Therefore, determining the mediators of 
central leptin signaling would provide a mechanism by which obesity leads to immune 
dysregulation.  
 
2. Central versus peripheral mediation of leptin’s effects on other immune responses 
 Despite our findings that central leptin receptor signaling was adequate to restore NK 
cell cytoxicity, there is a reasonable amount of data in support direct leptin signaling on other 
immune cells. Since we saw defects in monocyte/macrophage, dendritic cells and T cells, all 
of whose functions can be modulated by leptin, it would be important to test these other 
immune effectors to determine if leptin is necessary for their function. The fact the these cells 
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signal through pathways similar to NK cells, determining how leptin signaling affects their 
function, may lead to a better understanding about how leptin’s effects are mediated.  
 
3. Memory response to influenza infection 
 Both B and T cells are an important component of the memory response. This 
response leads to sustained immunity to infectious pathogens and is the basis for vaccination. 
Memory, however, is derived from the initial immune response to infection. Thus, the 
primary response is a major determinant of the memory response. The immune defects that 
occur in obese mice during their primary response to influenza infection, strongly suggest 
that activation of memory responses will be impaired. Thus it will be important to determine 
if obese mice are able to induce effective memory responses, as it will indicate a whether 
effective responses to vaccines are affected by obesity.  
 
4. Different dietary fat sources 
 Dietary fat, in particular polyunsaturated fatty acids, modulate immune responses. 
Whether this modulation also occurs with different sources of saturated fat is unclear. 
Therefore studies that manipulate of the fatty acid source can be used to study the effects of 
fatty acids on immune function, as well as tease apart the effect of obesity versus fatty acids 
on immune function. 
 
F. Public Health Significance 
 The present studies provide evidence of significant dysregulation of host immune 
responses to influenza infection due to obesity. This has considerable impact given the 
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unparalleled increase in obesity rates worldwide, and the annual widespread incidence of 
influenza infection. Obesity is associated with a number of co-morbidities, some of which are 
also risk factors for influenza infection-related morbidity and mortality. These include: Type 
2 Diabetes; Cardiovascular disease; and Chronic Pulmonary Obstructive Disorder (281). 
However, our work points to the fact that obesity in the absence of these co-morbidities, also 
increases the risk of morbidity and mortality during influenza infection.  
 
 Interestingly, the influenza vaccine is recommended for individuals with chronic 
diseases, such as those mentioned above. Our data illustrate that the effectiveness of the 
influenza vaccine by be minimized by obesity due to its dysregulation of primary immune 
responses. Therefore, regardless of vaccination status, obesity may result in increased 
susceptibility to the adverse effects of influenza virus infection. This is especially important, 
given the threat of a ‘flu’ pandemic. 
 
 Outside the scope of influenza specifically, the studies presented here, point towards a 
mechanism by which obesity generally modulates immune responses. Therefore, research 
targeting the mechanism (282) by which occurs will be useful in preventing obesity-induced 
immune dysregulation.  
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